
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomed Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Biomed. Sci</journal-id><journal-title-group><journal-title>Journal of Biomedical Science</journal-title></journal-title-group><issn pub-type="ppub">1021-7770</issn><issn pub-type="epub">1423-0127</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32370770</article-id><article-id pub-id-type="pmc">7201962</article-id><article-id pub-id-type="publisher-id">654</article-id><article-id pub-id-type="doi">10.1186/s12929-020-00654-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Signaling in and out: long-noncoding RNAs in tumor hypoxia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kuo</surname><given-names>Tse-Chun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kung</surname><given-names>Hsing-Jien</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0417-9015</contrib-id><name><surname>Shih</surname><given-names>Jing-Wen</given-names></name><address><email>shihjw@tmu.edu.tw</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.59784.37</institution-id><institution-id institution-id-type="ISNI">0000000406229172</institution-id><institution>Institute of Molecular and Genomic Medicine, </institution><institution>National Health Research Institutes, </institution></institution-wrap>Zhunan, Miaoli County, 35053 Taiwan, ROC </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Graduate Institute of Cancer Biology and Drug Discovery, </institution><institution>College of Medical Science and Technology, Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan, ROC </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Ph.D. Program for Cancer Biology and Drug Discovery, </institution><institution>College of Medical Science and Technology, Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan, ROC </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution>Department of Biochemistry and Molecular Medicine, </institution><institution>Comprehensive Cancer Center, University of California at Davis, </institution></institution-wrap>Sacramento, CA 95817 USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>TMU Research Center of Cancer Translational Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 110 Taiwan, ROC </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Ph.D. Program for Translational Medicine, College of Medical Science and Technology, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan, ROC </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>27</volume><elocation-id>59</elocation-id><history><date date-type="received"><day>27</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Over the past few years, long non-coding RNAs (lncRNAs) are recognized as key regulators of gene expression at chromatin, transcriptional and posttranscriptional level with pivotal roles in various biological and pathological processes, including cancer. Hypoxia, a common feature of the tumor microenvironment, profoundly affects gene expression and is tightly associated with cancer progression. Upon tumor hypoxia, the central regulator HIF (hypoxia-inducible factor) is upregulated and orchestrates transcription reprogramming, contributing to aggressive phenotypes in numerous cancers. Not surprisingly, lncRNAs are also transcriptional targets of HIF and serve as effectors of hypoxia response. Indeed, the number of hypoxia-associated lncRNAs (HALs) identified has risen sharply, illustrating the expanding roles of lncRNAs in hypoxia signaling cascade and responses. Moreover, through extra-cellular vesicles, lncRNAs could transmit hypoxia responses between cancer cells and the associated microenvironment. Notably, the aberrantly expressed cellular or exosomal HALs can serve as potential prognostic markers and therapeutic targets. In this review, we provide an update of the current knowledge about the expression, involvement and potential clinical impact of lncRNAs in tumor hypoxia, with special focus on their unique molecular regulation of HIF cascade and hypoxia-induced malignant progression.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Tumor hypoxia</kwd><kwd>Long non-coding RNA</kwd><kwd>lncRNA</kwd><kwd>HIF-1&#x003b1;</kwd><kwd>Hypoxia-associated lncRNAs</kwd><kwd>HAL</kwd><kwd>Extracellular vesicles</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010002</institution-id><institution>Ministry of Education</institution></institution-wrap></funding-source><award-id>TMU Research Center of Cancer Translational Medicine</award-id><award-id>TMU Research Center of Cancer Translational Medicine</award-id><principal-award-recipient><name><surname>Kung</surname><given-names>Hsing-Jien</given-names></name><name><surname>Shih</surname><given-names>Jing-Wen</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004663</institution-id><institution>Ministry of Science and Technology, Taiwan</institution></institution-wrap></funding-source><award-id>MOST108-2321-B-010-013-MY2</award-id><award-id>MOST108-2320-B-038-011</award-id><award-id>MOST107-2320-B-038-055-MY3</award-id><award-id>MOST108-2320-B-038-009-MY2</award-id><award-id>MOST105-2321-B-400-011-MY3</award-id><principal-award-recipient><name><surname>Kuo</surname><given-names>Tse-Chun</given-names></name><name><surname>Kung</surname><given-names>Hsing-Jien</given-names></name><name><surname>Shih</surname><given-names>Jing-Wen</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004700</institution-id><institution>Taipei Medical University</institution></institution-wrap></funding-source><award-id>TMU106-AE1-B52</award-id><principal-award-recipient><name><surname>Shih</surname><given-names>Jing-Wen</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><sec id="Sec2"><title>Hypoxia-associated lncRNAs (HALs) emerging as newly driving factors in tumorigenesis</title><p id="Par43">In rapidly growing solid tumors, hypoxia is a common, microenvironmental characteristics, caused by insufficient vascularization, and the high tumor metabolic demands [<xref ref-type="bibr" rid="CR1">1</xref>]. Accumulating evidence has demonstrated that tumor hypoxia is involved in the initial oncogenic transformation, but is also tightly linked to aggressive cancer phenotypes, such as metastases, recurrences and resistance to therapy [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Upon hypoxia, to survive, cancer cells co-opt the fundamental adaptive responses to this stress through modulating the central mediator of hypoxic response, the hypoxia-inducible factor-1 (HIF-1) complex.</p><p id="Par44">The HIF-1 complex is a heterodimeric assembly of bHLH-PAS (<underline>b</underline>asic <underline>h</underline>elix-<underline>l</underline>oop-<underline>h</underline>elix DNA binding proteins of the <underline>P</underline>ER-<underline>A</underline>RNT-<underline>S</underline>IM family) transcriptional factors, comprised of a constitutively expressed, stable HIF-1&#x003b2; subunit and an oxygen-sensitive HIF-1&#x003b1; subunit that determines HIF-1 activity [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. In mammals, two HIF-1&#x003b1; homologs, HIF-2&#x003b1; and HIF-3&#x003b1; (also known as IPAS-1; inhibitory PAS (Per/Arnt/Sim) domain protein), have been identified. Similar to HIF-1&#x003b1;, HIF-2&#x003b1; is also sensitive to oxygen concentration and can interact with HIF-1&#x003b2; to form the HIF-2 heterodimeric complex. Due to the structural similarity in DNA binding and dimerization domains as well as the difference in their transactivation domains, HIF-1&#x003b1; and HIF-2&#x003b1; regulate both common as well as distinct sets of target genes. Meanwhile, HIF-3&#x003b1;, an isoform lacking the transactivation domain, has a dominant negative effect on HIF-dependent gene transcription [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par45">In the presence of sufficient oxygen, HIF-1&#x003b1; subunits are post-translationally modified by a family of dioxygenases (prolyl hydroxylase domain-containing dioxygenases PHD1, 2 and 3, also known as EGLN1-3, Egl-9 family hypoxia inducible factor 1-3,). Upon hydroxylation, HIF-1&#x003b1; subunits are recognized by the E3 ubiquitin ligase, VHL (von Hippel-Lindau tumor suppressor protein), leading to the poly-ubiquitination and subsequent rapid degradation through the ubiquitin-proteasome pathway (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Under hypoxic conditions, the PHD dioxygenase activity is inhibited, and the accumulated HIF-1&#x003b1; subunit translocates into the nucleus, dimerizing with HIF-1&#x003b2; and binding to the HREs (hypoxia response elements; the consensus 5&#x02032;-(A/G)CGTG-3&#x02032; nucleotide sequence) within the promoter regions of HIF target genes to stimulate downstream transcriptional activation of multiple hypoxia responsive genes (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a), eliciting a wide spectrum of cellular adaptations, such as decreased apoptosis, enhanced angiogenesis, proliferation, migration and invasion [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. In addition to protein coding genes, it has been widely acknowledged that the non-coding transcriptome is also responsive to hypoxia and play critical roles in the hypoxic response and HIF-1 associated cancer progression [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>].
<fig id="Fig1"><label>Fig. 1</label><caption><p>Regulations of HIF-1 activity by HALs. <bold>a</bold> Regulation of HIF-1. Under normoxia (green arrows), HIF-1&#x003b1; subunit is hydroxylated by PHDs (prolyl hydroxylase domain proteins). Hydroxylation residues within HIF-1&#x003b1; facilitates interaction of HIF-1&#x003b1; with the E3 ubiquitin ligase VHL protein, targeting HIF-1&#x003b1; for polyubiquitination and subsequent proteasome-dependent degradation. Upon hypoxia (red arrows), the PHDs and other prolyl hydroxylases are inhibited, leading to HIF-1&#x003b1; stabilization and translocation into nucleus. After dimerization with its transcriptional partner HIF-1&#x003b2; and recruitment of co-activators (e.g. CBP/p300), the HIF-1 heterodimer binds the HRE (hypoxia response element) of target genes to regulate transcription. <bold>b</bold> Transcriptional co-activator. Hypoxia-induced <italic>LncHIFCAR</italic> could directly interact with HIF-1&#x003b1; and facilitate the recruitment of HIF-1&#x003b1; and p300 cofactor to the target loci, thereby upregulating HIF-1 target genes. <bold>c</bold> Recruitment of transcription factor. HIF-1&#x003b1;-induced <italic>LncRNA-MTA2TR</italic> could recruit ATF3 to the promoter area of <italic>MTA2</italic>, thereby transcriptionally upregulating the expression of oncogenic MTA2. MTA2 can subsequently enhance HIF-1&#x003b1; protein accumulation via deacetylation, forming a feedback loop to amplify HIF-1 signaling. <bold>d</bold> mRNA stability control. The expression of <italic>lncRNA-LET</italic> is repressed through hypoxia-induced HDAC3, which reduces the histone H3 and H4 acetylation at the <italic>LncRNA-LET</italic> promoter. Decreased <italic>lncRNA-LET</italic> expression reduces the <italic>lncRNA-LET</italic>&#x02013;mediated degradation of HIF-1&#x003b1; negative regulator, NF90, leading to HIF-1&#x003b1; accumulation. <bold>e </bold>ceRNA/miRNA sponge. Hypoxia-induced <italic>H19</italic> could upregulate HIF-1&#x003b1; expression by absorbing miRNA let-7 and nullifying let-7-mediated <italic>HIF1A</italic> mRNA suppression. <bold>f </bold>Molecular decoy. <italic>lincRNA-p21</italic> is able to disrupt the interaction between HIF-1&#x003b1; and its negative regulator VHL via separate binding to both HIF-1&#x003b1; and VHL, thereby blocking VHL-dependent HIF-1&#x003b1; degradation. <bold>g </bold>Complex scaffold. <italic>LINK-A</italic>-mediated recruitment and enzymatic activation of BRK and LRRK2 kinases could facilitate phosphorylation of HIF-1&#x003b1; at specific residues. These phosphorylation modifications prevent subsequent HIF-1&#x003b1; degradation and enhance the association between HIF-1&#x003b1; and cofactor p300, thereby upregulating HIF-1 target genes. See text for a more detailed discussion</p></caption><graphic xlink:href="12929_2020_654_Fig1_HTML" id="MO1"/></fig></p><p id="Par46">With recent advances in high-throughput sequencing, it is recognized that only a small fraction (&#x0003c;&#x02009;2%) of the transcriptional output encodes proteins whereas the vast majority encode a variety of non-coding RNAs. Among these non-coding RNA species, long (&#x0003e;&#x02009;200&#x02009;bp) non-coding RNAs (lncRNAs) are a large class of regulatory transcripts [<xref ref-type="bibr" rid="CR17">17</xref>], including lincRNAs (long intergenic RNAs), long intronic ncRNAs, pseudogenes, TCRs (transcribed ultra-conserved regions), asRNAs (antisense RNAs) and eRNAs (enhancer RNAs) [<xref ref-type="bibr" rid="CR18">18</xref>]. According to the latest human genome annotation (GRch38, GENCODE release 33, January 2020; <ext-link ext-link-type="uri" xlink:href="http://www.gencodegenes.org">www.gencodegenes.org</ext-link>), 48,438 transcripts originating from 17,952 loci were identified as lncRNAs. Although less than 1% has been functionally annotated, growing evidence suggested the vital roles of these lncRNAs in regulation of gene expression at various stages, such as imprinting, transcription, RNA interference, RNA splicing, and translation control [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. It is now believed that the distinctive RNA biochemical properties, such as base-pairing ability, dynamic expression and flexible structure, endow these lncRNAs with multi-functionality [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. Collectively, it is now well appreciated that, through acting as signals, decoys, guides or scaffolds, lncRNA could act as a crucial player of biological regulation [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par47">Over the last few years, a large number of dysregulated lncRNAs have been associated with numerous diseases, including cancer [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. While a few cancer-associated lncRNAs have been well characterized [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], the functions of most remain largely unknown. Dysregulation of many cancer-associated lncRNAs is linked to both clinicopathological features and survival outcomes of patients, suggesting that functional annotation of these lncRNAs will eventually identify new venues for early diagnosis and therapy of cancer [<xref ref-type="bibr" rid="CR39">39</xref>]. Several studies have shown that the modulation of lncRNAs in response to hypoxia could play a regulatory role in HIF signaling cascade [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Here, we refer to these unique transcripts as &#x0201c;hypoxia-associated lncRNAs&#x0201d; (HALs). These RNA molecules are involved in multiple hypoxia-driven cancer progression pathways. In this review, we provide an updated summary of the tumor HALs, with a specific emphasis on the crosstalk between these lncRNA species and cellular hypoxia response (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Additional&#x000a0;file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>: Table S1). We address current models describing the functional involvement of these new players in cancer progression, highlighting their relevant clinical potential as cancer biomarkers or therapeutic targets. Our discussion is centered on tumor hypoxia. For the functional roles of lncRNAs in hypoxia-induced kidney/hepatic/myocardial injury and neuromuscular or cardiovascular diseases, interested readers are referred to a number of comprehensive reviews published in recent years [<xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR132">132</xref>].
<table-wrap id="Tab1"><label>Table 1</label><caption><p>| HAL-mediated HIF signaling control and cancer progression</p></caption><table frame="hsides" rules="groups"><thead><tr><th>lncRNA</th><th>Status upon hypoxia</th><th>HIF involvement</th><th>Cancer Types</th><th>Clinical association</th><th>Functional Impact</th><th>Interactor</th><th>Target/Effect</th><th>Mechanistic Classification</th><th>Refs</th></tr></thead><tbody><tr><td rowspan="5"><p><italic>aHIF</italic></p><p><italic>(HIF1A-AS2)</italic></p></td><td>Not further induced in nonpapillary disease, but can be induced in lymphocytes</td><td><p>N.D.</p><p>(2 Putative HREs)</p></td><td>Renal carcinoma</td><td>&#x02022; Up-regulated in non-papillary clear-cell renal carcinoma</td><td>N.D.</td><td><italic>HIF1A</italic> mRNA</td><td><italic>HIF1A</italic> mRNA stability</td><td><p><bold>mRNA stability control</bold></p><p>(Binding of <italic>HIF1A-AS2</italic> to the <italic>HIF1A</italic> mRNA 3&#x02032;-UTR could possibly expose AU-rich elements and thus increase the degradation of <italic>HIF1A</italic> mRNA)</p></td><td>[<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Human umbilical vein endothelial cells (HUVECs)</td><td>&#x02022; Up-regulated in HUVECs in hypoxia</td><td><p>HUVECs viability &#x02191;</p><p>Migration ability &#x02191;</p><p>Tube formation &#x02191;</p></td><td>miR-153-3p</td><td>The expression of HIF-1&#x003b1;</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-153-3p-mediated repression of HIF-1&#x003b1; expression)</p></td><td>[<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Bladder cancer</td><td>&#x02022; Upregulated in bladder cancer after cisplatin treatment</td><td>Cisplatin resistance &#x02191;</td><td>N.D.</td><td>Promoting <italic>HMGA1</italic> expression</td><td><p><bold>Transcriptional regulation</bold></p><p>(HIF1A-AS2 promoting the expression of <italic>HMGA1</italic>, which physically interacts with p53, p63, and p73, and therefore inhibits their transcriptional activity on <italic>Bax</italic>)</p></td><td>[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td>Up-regulated</td><td><p>HIF-1&#x003b1; and/or HIF-2&#x003b1; dependent</p><p>(2 HREs identified)</p></td><td><p>Mesenchymal Glioblastoma</p><p>Stem-like Cells (M-GSCs)</p></td><td>&#x02022; Upregulated in M-GSCs</td><td><p>Growth of M-GSCs &#x02191;</p><p>Neurosphere-forming capacity of M-GSCs &#x02191;</p><p>Glioblastoma tumor growth &#x02191;</p></td><td>IGF2BP2 and DHX9</td><td>Maintenance of expression of <italic>HMGA1</italic></td><td><p><bold>Complex scaffold</bold></p><p>(The direct interaction among <italic>HIF1A-AS2</italic>, IGF2BP2 and DHX9 is needed for <italic>HMGA1</italic> expression)</p></td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Epithelial ovarian cancer (EOC)</td><td>&#x02022; Up-regulated in EOC</td><td><p>Cell apoptosis &#x02193;</p><p>Cell proliferation &#x02191;</p><p>Tumorigenesis &#x02191;</p><p>Tumor growth &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(May partially through the <italic>aHIF</italic>-mediated regulation of certain key mitochondrial apoptosis pathway-related genes, including Bcl-2, Bax, Caspase-7, and Caspase-9)</p></td><td>[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td><italic>AGAP2-AS1</italic></td><td>Up-regulated</td><td>N.D.</td><td>Hepatocellular carcinoma (HCC)</td><td><p>&#x02022; Up-regulated in HCC</p><p>&#x02022; Correlated with adverse clinical features and poor prognosis of HCC</p></td><td><p>Cell proliferation &#x02191;</p><p>Migration and invasion &#x02191;</p><p>EMT progression &#x02191;</p><p>Apoptosis &#x02193;</p></td><td>miR-16-5p</td><td>The expression of ANXA11</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-16-5p-mediated repression of ANXA11)</p></td><td>[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td><italic>ANRIL (CDKN2B-AS1)</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Osteosarcoma</td><td>&#x02022; Up-regulated in osteosarcoma</td><td><p>Hypoxic viability &#x02191;</p><p>Hypoxia-induced Invasion &#x02191;</p><p>Hypoxia-induced apoptosis &#x02193;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(Possibly through epigenetic modification)</p></td><td>[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td><italic>BC005927</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(2 HREs identified)</p></td><td>Gastric cancer (GC)</td><td><p>&#x02022; Up-regulated in GC</p><p>&#x02022; Correlated with higher tumor-node-metastasis stages and poorer prognoses</p></td><td>Metastasis &#x02191;</td><td>N.D.</td><td>N.D.</td><td><p><bold>Transcriptional regulation</bold></p><p>(The neighboring gene, <italic>EPHB4</italic>, a metastasis-related gene, is regulated by <italic>BC005927</italic>)</p></td><td>[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td><italic>BX111887 (ZEBTR)</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Pancreatic cancer (PC)</td><td><p>&#x02022; Upregulated in PC</p><p>&#x02022; Correlated with late TNM stage, lymphatic invasion and distant metastasis</p></td><td><p>Proliferation &#x02191;</p><p>Migration &#x02191;</p><p>Invasion &#x02191;</p></td><td>YB1</td><td><italic>ZEB1</italic> promoter</td><td><p><bold>Transcriptional regulation</bold></p><p>(<italic>BX111</italic> promotes <italic>ZEB1</italic> transcription by recruiting YB1 to <italic>ZEB1</italic> promoter)</p></td><td>[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td><italic>CASC9</italic></td><td>N.D.</td><td>N.D.</td><td>Nasopharyngeal carcinoma (NPC)</td><td>Up-regulated in NPC tissues</td><td><p>Glycolysis and tumorigenesis &#x02191;</p><p>Cell growth &#x02191;</p></td><td>HIF-1&#x003b1;</td><td>The stability of HIF-1&#x003b1;</td><td><p><bold>Protein Stability</bold></p><p>(<italic>CASC9</italic> interacts with HIF-1&#x003b1; and enhances the stabilization of HIF-1&#x003b1;)</p></td><td>[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td><p><italic>CF129</italic></p><p><italic>(lncRNA-CF129145.1)</italic></p></td><td>Down-regulated</td><td>Downregulated by binding of HIF-1&#x003b1;/HDAC1 complex to CF129 promoter</td><td>Pancreatic cancer (PC)</td><td><p>&#x02022; Down-regulated in PC</p><p>&#x02022; Low CF129 expression predicted short overall survival</p></td><td>Invasion and metastasis &#x02193;</td><td>p53 and E3 ligase MKRN1</td><td><italic>FOXC2</italic> transcription</td><td><p><bold>Post-Translational modification</bold></p><p>(<italic>CF129</italic> directly binds to p53 and E3 ligase MKRN1, inducing p53 protein ubiquitination and degradation, and thereby suppressing <italic>FOXC2</italic> transcription)</p></td><td>[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td><italic>CPS1-IT1</italic></td><td><p>Down-regulated</p><p>(treatment of hypoxia mimetic, CoCl<sub>2</sub>)</p></td><td>N.D.</td><td>Colorectal cancer</td><td>Down-regulated in colorectal cancer</td><td>EMT and autophagy &#x02193;</td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(May partially through suppressing expression levels of HIF-1&#x003b1;, LC3-I, LC3-II, Beclin-1 and EMT associated proteins under hypoxia)</p></td><td>[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td><p><italic>CRPAT4</italic></p><p><italic>(RP11-225B17)</italic></p></td><td>Down-regulated</td><td>HIF-1&#x003b1; dependent, HIF-2&#x003b1; independent</td><td><p>Clear cell renal cell</p><p>carcinoma (ccRCC)</p></td><td><p>&#x02022; Up-regulated in ccRCC</p><p>&#x02022; Associated with poor overall survival and progression-free survival</p></td><td><p>Cell migration &#x02191;</p><p>Proliferation &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(May partially through the <italic>CRPAT4</italic>-mediated regulation of migration-associated gene <italic>AVL9</italic> expression)</p></td><td>[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td><italic>DANCR</italic></td><td>N.D.</td><td>N.D.</td><td>Nasopharyngeal carcinoma (NPC)</td><td><p>&#x02022; Up-regulated in NPC</p><p>&#x02022; Associated with poor prognosis</p></td><td><p>Metastasis &#x02191;</p><p>Invasion &#x02191;</p></td><td><p>NF90/NF45</p><p>complex</p></td><td>HIF-1&#x003b1; mRNA stability</td><td><p><bold>mRNA stability control</bold></p><p>(<italic>DANCR</italic> could increase HIF-1&#x003b1; mRNA stability through interacting with the NF90/NF45 complex)</p></td><td>[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td><italic>DARS-AS1</italic></td><td>Up-regulated</td><td>HIF-1&#x003b1; dependent, But HIF-2&#x003b1; independent (2 HREs identified)</td><td>Myeloma</td><td><p>&#x02022; Up-regulated in myeloma</p><p>&#x02022; Correlated with poor prognosis</p></td><td><p>Survival &#x02191;</p><p>Tumorigenesis &#x02191;</p></td><td>RBM39</td><td>RBM39 stability</td><td><p><bold>Post-Translational modification</bold></p><p>(The interaction between <italic>DARS-AS1</italic> and RNA-binding protein 39 (RBM39) impedes the interaction between RBM39 and its E3 ubiquitin ligase RNF147, preventing RBM39 from degradation)</p></td><td>[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td><italic>EIF3J-AS1 (EIF3J-DT)</italic></td><td>Up-regulated</td><td>N.D.</td><td>Hepatocellular carcinoma (HCC)</td><td><p>&#x02022; Up-regulated in HCC tissues</p><p>&#x02022; Correlated with tumor size, vascular invasion, tumor stage and poor prognosis</p></td><td><p>Cell proliferation &#x02191;</p><p>Migration &#x02191;</p><p>Invasion &#x02191;</p></td><td>miR-122-5p</td><td>The expression of CTNND2</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-122-5p-mediated repression of CTNND2)</p></td><td>[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td><italic>ENST00000480739 (RPL13AP23)</italic></td><td>N.D.</td><td>N.D.</td><td><p>Pancreatic ductal adenocarcinoma</p><p>(PDAC)</p></td><td><p>&#x02022; Down-regulated in PDAC</p><p>&#x02022; Associated with tumor node metastasis (TNM) stage and lymph node metastasis</p><p>&#x02022; Independent risk factor for PDAC survival following surgery</p></td><td><p>Invasion &#x02193;</p><p><italic>OS-9</italic> mRNA &#x00026; protein &#x02191;</p></td><td>N.D.</td><td>Transcription of <italic>OS-9</italic> (Negative regulation of HIF-1&#x003b1;)</td><td><p><bold>Epigenetic and transcriptional regulation</bold></p><p>(<italic>ENST00000480739</italic> induces <italic>OS-9</italic> expression at the transcriptional level, possibly through modifying the H3K27 acetylation level of <italic>OS9</italic> gene promoter)</p></td><td>[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td><italic>FALEC</italic></td><td>Up-regulated</td><td>HIF-1&#x003b1; inducible</td><td>Prostate cancer (PCa)</td><td><p>&#x02022; Up-regulated in PCa</p><p>&#x02022; Independent prognostic factor</p></td><td><p>Cell proliferation &#x02191;</p><p>Migration and invasion &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(May partially through the <italic>FALEC</italic>-mediated regulation of p21 and its downstream components expression)</p></td><td>[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td><italic>FAM201A</italic></td><td>N.D.</td><td>N.D.</td><td><p>Non-small cell lung cancer</p><p>(NSCLC)</p></td><td>&#x02022; Up-regulated in tissues obtained from NSCLC patients resistant to radiotherapy</td><td><p>Cell proliferation &#x02191;</p><p>Apoptosis (under X-ray irradiation) &#x02193;</p></td><td>miR-370</td><td>The expression of EGFR</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-370-mediated repression of EGFR)</p></td><td>[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td><italic>FEZF1-AS1</italic></td><td>N.D.</td><td>N.D.</td><td>Pancreatic cancer</td><td>&#x02022; Upregulated in pancreatic cancer</td><td><p>Cell proliferation &#x02191;</p><p>Invasion &#x02191;</p></td><td>miR-142 and miR-133a</td><td>The expression of HIF-1&#x003b1; and EGFR</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-142- and miR-133a-mediated repression of HIF-1&#x003b1; and EGFR expression)</p></td><td>[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td><italic>GAPLINC</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; (2 HREs identified)</p><p>(2 HREs)</p></td><td>Gastric cancer</td><td><p>&#x02022; Upregulated in GC</p><p>&#x02022; High expression of <italic>GAPLINC</italic> correlates with poorer survival</p><p>&#x02022; GAPLINC correlates with CD44 activation</p></td><td><p>Proliferation &#x02191;</p><p>Apoptosis &#x02193;</p><p>Invasion &#x02191;</p><p>Migration &#x02191;</p></td><td>miR-211-3p</td><td>The expression of CD44</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-211-3p-mediated repression of CD44)</p></td><td>[<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td rowspan="5"><italic>H19</italic></td><td>Up-regulated</td><td>N.D.</td><td>Breast cancer stem cells (BCSCs)</td><td>&#x02022; H19 expression strongly correlates with PDK1 in primary breast carcinomas</td><td><p>Glycolysis &#x02191;</p><p>BCSC maintenance &#x02191;</p></td><td>let-7</td><td>The expression of HIF-1&#x003b1;</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of let-7-mediated repression of HIF-1&#x003b1; expression)</p></td><td>[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Multiple Myeloma (MM)</td><td>N.D.</td><td><p>The expression of the hypoxia induced genes &#x02191;</p><p>Adhesion on stromal cells &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>HIF-1&#x003b1; nuclear translocation</bold></p><p>(<italic>H19</italic> is required for HIF-1&#x003b1; nuclear translocation and the expression of the hypoxia-induced genes, such as CXCR4 and Snail)</p></td><td>[<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(3 HREs identified)</p></td><td>Glioblastoma (GBM)</td><td><p>&#x02022; Up-regulated in GBM</p><p>&#x02022; Correlated with poor prognosis</p><p>&#x02022; The HIF-1&#x003b1; levels were positively correlated with H19 levels in GBM specimens</p></td><td><p>Migration and invasion &#x02191;</p><p>Tumor growth &#x02191;</p><p>EMT &#x02191;</p></td><td>miR-181d</td><td>The expression of &#x003b2;-catenin</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-181d-mediated repression of &#x003b2;-catenin expression)</p></td><td>[<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Prostate Cancer</td><td><p>&#x02022; Upregulated by estrogen or hypoxia</p><p>&#x02022; Reduced upon combined treatment</p></td><td><p>Cell motility &#x02193;</p><p>Invasion &#x02193;</p></td><td>N.D.</td><td>Repression of beta3 and beta4 Integrins</td><td><p><bold>Unclear mechanism</bold></p><p>(Combined Estrogen and Hypoxia treatment could cause H19 down-regulation, followed by up-regulation of both &#x003b2;3 and &#x003b2;4 Integrins and E-cadherin)</p></td><td>[<xref ref-type="bibr" rid="CR72">72</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Breast cancer, Non-small cell lung carcinoma (NSCLC)</td><td><p>&#x02022; Up-regulated in NSCLC with chronic obstructive pulmonary disease (COPD)</p><p>&#x02022; Up-regulated in all common metastatic sites tested</p></td><td><p>Migration and invasion &#x02191;</p><p>Tumor growth &#x02191;</p><p>EMT &#x02191;</p></td><td>N.D.</td><td>Up-regulation of miR-675-5p</td><td><p><bold>Unclear mechanism</bold></p><p>(<italic>H19</italic> could induce upregulation of miR-675-5p, whereas P53 is a target gene of miR-675-5p and P53 downstream target genes involved in EMT, survival and tumorigenesis are thereby repressed)</p></td><td>[<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td><italic>HAS2-AS1</italic></td><td>Up-regulated</td><td>HIF-1&#x003b1; dependent (1 HRE identified)</td><td>Oral squamous cell carcinoma (OSCC)</td><td>&#x02022; Up-regulated in OSCC</td><td>EMT &#x02191;</td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(<italic>HAS2-AS1</italic>-mediated hypoxia-induced EMT is dependent on cell-adhesion molecule CD44 and RHAMM)</p></td><td>[<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td rowspan="2"><italic>HIF2PUT</italic></td><td>N.D.</td><td>N.D.</td><td>Osteosarcoma</td><td>&#x02022; Expression of <italic>HIF2PUT</italic> is correlated with <italic>HIF2A</italic> mRNA</td><td><p>Cell proliferation and migration &#x02193;</p><p>Expression of CSC marker CD133 &#x02193;</p><p>Sphere-forming ability &#x02193;</p></td><td>N.D.</td><td>Transcription of <italic>HIF2A</italic></td><td><p><bold>Transcriptional regulation</bold></p><p>(HIF-2&#x003b1; was positively regulated by lncRNA <italic>HIF2PUT</italic>)</p></td><td>[<xref ref-type="bibr" rid="CR76">76</xref>]</td></tr><tr><td>N.D,</td><td>N.D.</td><td>Osteosarcoma cancer stem cell</td><td><p>&#x02022; Down-regulated in osteosarcoma cell lines</p><p>&#x02022; A strong positive correlation between relative HIF2PUT and HIF-2&#x003b1; level in osteosarcoma cancer tissues</p></td><td><p>Proliferation &#x02193;</p><p>Migration and invasion &#x02193;</p><p>Sphere-formation &#x02193;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(May partly through <italic>HIF2PUT</italic>-mediated regulation of HIF-2 expression)</p></td><td>[<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td><italic>HINCUT-1 (uc.475)</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(3 HREs identified)</p></td><td>Colon and breast cancer cell lines</td><td>N.D.</td><td>Hypoxic cell proliferation &#x02191;</td><td>N.D.</td><td>N.D.</td><td><p><bold>Transcriptional regulation</bold></p><p>(<italic>HINCUT-1</italic> is required for the expression of <italic>OGT</italic> mRNA expression and global O-GlcNAcylation of proteins)</p></td><td>[<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td rowspan="2"><italic>HOTAIR</italic></td><td>N.D.</td><td>N.D.</td><td>Renal cell carcinoma</td><td>&#x02022; Upregulated and correlated with tumor progression</td><td><p>RCC proliferation &#x02191;</p><p>Migration and EMT &#x02191;</p><p>Apoptosis &#x02193;</p></td><td>miR-217</td><td>The expression of HIF-1&#x003b1;/AXL</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-217-mediated repression of HIF-1&#x003b1;/AXL expression)</p></td><td>[<xref ref-type="bibr" rid="CR79">79</xref>]</td></tr><tr><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Non-small cell lung carcinoma (NSCLC)</td><td>&#x02022; High level of <italic>HOTAIR</italic> is associated with poor clinical outcome in multiple cancers</td><td><p>Cell proliferation under hypoxia &#x02191;</p><p>Invasion &#x00026; migration under hypoxia &#x02191;</p><p>Apoptosis under hypoxia &#x02193;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(Possibly through <italic>HOTAOR</italic>-mediated epigenetic modification)</p></td><td>[<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]</td></tr><tr><td><italic>HOTTIP</italic></td><td>Up-regulated</td><td>HIF-1&#x003b1; dependent</td><td>Glioma</td><td><p>&#x02022; Up-regulated in glioma</p><p>&#x02022; Associated with metastasis and poor patient survival</p></td><td><p>EMT &#x02191;</p><p>Invasion &#x02191;</p><p>Migration &#x02191;</p></td><td>miR-101</td><td>The expression of <italic>ZEB1</italic></td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-101-mediated repression of <italic>ZEB1</italic>)</p></td><td>[<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td><italic>IDH1-AS1</italic></td><td>N.D.</td><td><p>N.D.</p><p>(c-Myc-mediated repression)</p></td><td>Multiple cell lines (HeLa, HCT116, H1299, P493 and 293&#x02009;T)</td><td>N.D.</td><td>Glycolysis &#x02193;</td><td>IDH1</td><td>IDH1 dimerization</td><td><p><bold>Protein Dimerization</bold></p><p>(<italic>IDH1-AS1</italic> interacts with IDH1 and promotes Its Homo-dimerization)</p></td><td>[<xref ref-type="bibr" rid="CR83">83</xref>]</td></tr><tr><td><italic>LINC01436</italic></td><td>Up-regulated</td><td>N.D.</td><td><p>Non-small cell lung cancer</p><p>(NSCLC)</p></td><td><p>&#x02022; Up-regulated in NSCLC</p><p>&#x02022; Associated with poor overall survival</p></td><td><p>Cell growth &#x02191;</p><p>Migration and invasion &#x02191;</p></td><td>miR-30a-3p</td><td>The expression of EPAS1</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-30a-3p-mediated repression of EPAS1)</p></td><td>[<xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td rowspan="2"><italic>lincRNA-p21 (TP53COR1)</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent &#x00026; preference</p><p>(2 HREs identified)</p></td><td>Cervical, lung and breast cancer cell lines</td><td>N.D.</td><td><p>Hypoxic glycolysis &#x02191;</p><p>Tumor growth &#x02191;</p></td><td>HIF-1&#x003b1; and VHL</td><td>The disruption of the VHL-HIF-1&#x003b1; interaction</td><td><p><bold>Protein-Protein Interaction Decoy</bold></p><p>(Stabilization of HIF-1&#x003b1; by disrupting the VHL-HIF-1&#x003b1; Interaction)</p></td><td>[<xref ref-type="bibr" rid="CR85">85</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Hepatoma, glioma</td><td>N.D.</td><td><p>Apoptosis &#x02193;</p><p>Cell proliferation and motility &#x02191;</p><p>Autophagy &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(<italic>LincRNA-p21</italic> could promote autophagy of hypoxic tumor cells by up-regulating HIF-1&#x003b1; protein levels and suppressing Akt/mTOR/P70S6K signaling pathways)</p></td><td>[<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td><italic>linc-ROR</italic></td><td>Up-regulated</td><td>N.D.</td><td>Hepatocellular cancer</td><td>Up-regulated in malignant liver cancer cells</td><td><p>Cell viability during hypoxia &#x02191;</p><p>Tumor growth &#x02191;</p></td><td>miR-145</td><td>The expression of <italic>p70S6K1</italic> (<italic>RPS6KB1</italic>)</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR145-mediated repression of p70S6K1 expression)</p></td><td>[<xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td><p><italic>LINK-A</italic></p><p><italic>(LINC01139)</italic></p></td><td>N.D.</td><td>N.D.</td><td>Triple-negative breast cancer</td><td><p>&#x02022; Upregulated in TNBC</p><p>&#x02022; High levels of <italic>LINK-A</italic> correlated with unfavorable recurrence-free survival for breast cancer patients</p></td><td><p>Glycolysis &#x02191;</p><p>Tumor growth &#x02191;</p></td><td>BRK and LRRK2 kinase</td><td>HIF-1&#x003b1; phosphorylation</td><td><p><bold>Complex scaffold</bold></p><p>(<italic>LINK-A</italic> facilitates the recruitment of BRK and LRRK2 kinase activation, thereby causing HIF-1&#x003b1; stabilization, HIF-1&#x003b1;/p300 interaction, and activation of HIF-1&#x003b1; transcriptional programs under normoxic conditions)</p></td><td>[<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td><italic>LncHIFCAR (MIR31HG)</italic></td><td>Up-regulated</td><td>HIF-1&#x003b1; dependent</td><td>Oral cancer</td><td><p>&#x02022; Up-regulated in oral cancer</p><p>&#x02022; High levels of <italic>LncHIFCAR</italic> predicted worse overall survival and recurrence-free survival</p></td><td><p>Hypoxic glycolysis &#x02191;</p><p>Tumor metastasis &#x02191;</p><p>Invasion and migration &#x02191;</p><p>Hypoxic cell proliferation &#x02191;</p><p>Sphere-forming ability &#x02191;</p></td><td>HIF-1&#x003b1;</td><td>Activation of HIF-1 signaling</td><td><p><bold>Transcriptional regulation</bold></p><p>(<italic>LncHIFCAR</italic> acts as HIF-1&#x003b1; coactivator)</p></td><td>[<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td><italic>lncRNA-AK058003</italic></td><td>Up-regulated</td><td>N.D.</td><td>Gastric cancer</td><td>Up-regulated in GC</td><td><p>Invasion &#x00026; migration &#x02191;</p><p>Metastasis &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Epigenetic regulation</bold></p><p>(<italic>AK058003</italic> expression is positively correlated with <italic>SNCG</italic> expression and <italic>SNCG</italic> promoter demethylation)</p></td><td>[<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td><italic>lncRNA-EFNA3</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Breast cancer</td><td>A strong correlation between high <italic>EFNA3</italic> expression and shorter metastasis-free survival in breast cancer patients</td><td><p>Cell extravasation &#x02191;</p><p>Metastatic dissemination &#x02191;</p></td><td>miR-210</td><td>The expression of EFNA3</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-210-mediated repression of EFNA3)</p></td><td>[<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr><tr><td><p><italic>lncRNA-HAL</italic></p><p><italic>(lnc-METTL16-2)</italic></p></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(3 putative HREs found)</p></td><td>Breast cancer</td><td>Up-regulated in triple negative breast cancer</td><td><p>Migration &#x02191;</p><p>Cancer stem cell phenotype &#x02191;</p><p>Mammospheres &#x02191;</p><p>Clonogenic growth &#x02191;</p></td><td>Histones and hnRNPs.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(The binding of <italic>lncRNA-HAL</italic> to histones and hnRNPs may suggest a participation at the chromatin level and transcriptional regulation)</p></td><td>[<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td><italic>lncRNA-LET (NPTN-IT1)</italic></td><td>Down-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(Indirect: Histone deacetylation)</p></td><td>Lung squamous-cell cancer (LSCC), hepatocellular carcinoma (HCC) and colorectal cancer (CRC)</td><td><p>&#x02022; Down-regulated in in LSCC, HCC and CRC</p><p>&#x02022; Correlated with hypoxia, histone acetylation disorder and metastasis in HCC</p></td><td><p>Metastasis &#x02193;</p><p>Invasion &#x02193;</p></td><td>NF90 (RNA-binding protein)</td><td><italic>HIF1A</italic> mRNA stability</td><td><p><bold>mRNA stability control</bold></p><p>(The association between <italic>lncRNA-LET</italic> and NF90 protein enhanced the degradation of NF90, thereby decreasing <italic>HIF1A</italic> mRNA)</p></td><td>[<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td><p><italic>lncRNA-SARCC</italic></p><p><italic>(lnc-P2RY1-1)</italic></p></td><td>VHL-dependent</td><td><p>HIF-2&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Renal cell carcinoma</td><td>Differentially regulated by hypoxia in a von Hippel-Lindau (VHL)-dependent manner in RCC clinical specimens</td><td><p>Hypoxic cell cycle progression (VHL-restored RCC cells) &#x02191;</p><p>Hypoxic cell cycle progression (VHL-mutant RCC cells) &#x02193;</p></td><td>AR (androgen receptor)</td><td>AR ubiquitination and degradation</td><td><p><bold>Post-Translational modification</bold></p><p>(<italic>lncRNA-SARCC</italic> could promote AR degradation via ubiquitin-mediated proteolysis to suppress AR/HIF-2&#x003b1;/C-MYC signals)</p></td><td>[<xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td><italic>lncTCF7 (WSPAR)</italic></td><td>Up-regulated</td><td>N.D.</td><td>Glioma</td><td><p>&#x02022; Up-regulated in glioma</p><p>&#x02022; Associated with WHO grade and tumor size</p></td><td><p>Cell migration &#x02191;</p><p>Proliferation &#x02191;</p><p>Tumorigenicity &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(<italic>LncTCF7</italic> could promote the migration and proliferation of glioma cell partially through activating the Wnt signalling pathway)</p></td><td>[<xref ref-type="bibr" rid="CR95">95</xref>]</td></tr><tr><td rowspan="3"><italic>MALAT1</italic></td><td>Up-regulated</td><td><p>HIF-2&#x003b1; dependent &#x00026; preference</p><p>(1HRE)</p></td><td>Hepatocellular carcinoma</td><td>N.D.</td><td><p>Cell growth &#x02191;</p><p>Glycolysis &#x02191;</p><p>Migration &#x00026; invasion &#x02191;</p><p>Vasculature formation &#x02191;</p><p>Metastasis &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Post-Translational modification</bold></p><p>(<italic>MALAT1</italic> decreases hydroxylation of HIF-1&#x003b1;/HIF-2&#x003b1;, possibly through disassociation of the VHL protein from HIF-1&#x003b1;/HIF-2&#x003b1;)</p></td><td>[<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Lung adenocarcinoma</td><td>N.D.</td><td><p>Proliferation &#x02191;</p><p>Migration &#x02191;</p><p>Invasion &#x02191;</p></td><td>PTB-associated splicing factor (PSF)</td><td><italic>GAGE6</italic> promoter</td><td><p><bold>Transcriptional regulation</bold></p><p>(The physical interaction of <italic>MALAT1</italic> and PSF released the binding of PSF to <italic>GAGE6</italic> promoter)</p></td><td>[<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Hepatocellular carcinoma</td><td>N.D.</td><td><p>Proliferation &#x02191;</p><p>Migration and invasion &#x02191;</p><p>Apoptosis &#x02193;</p></td><td>miR-200a</td><td>N.D.</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-200a)</p></td><td>[<xref ref-type="bibr" rid="CR100">100</xref>]</td></tr><tr><td><italic>MEG3</italic></td><td>Up-regulated</td><td>N.D.</td><td>Pheochromocytoma</td><td>N.D.</td><td>Hypoxia-induced PC12 cell injury &#x02191;</td><td>Methylation proteins (DNMT3a, DNMT3b, and MBD1)</td><td><italic>TIMP2</italic> promoter methylation</td><td><p><bold>Epigenetic regulation</bold></p><p>(<italic>MEG3</italic> recruited methylation proteins DNMT3a, DNMT3b, and MBD1 and accelerated <italic>TIMP2</italic> promoter methylation, which in turn inhibited its expression)</p></td><td>[<xref ref-type="bibr" rid="CR101">101</xref>]</td></tr><tr><td><italic>MTA2TR</italic></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Pancreatic cancer (PC)</td><td>Upregulated in PC tissues</td><td><p>Cell proliferation &#x02191;</p><p>Invasion &#x02191;</p></td><td>Activating transcription factor 3 (ATF3)</td><td><p>The expression of MTA2</p><p>(MTA2 stabilizes the HIF-1&#x003b1; via deacetylation)</p></td><td><p><bold>Transcriptional regulation</bold></p><p>(<italic>MTA2TR</italic> transcriptionally upregulates MTA2 expression by recruiting ATF3 to the promoter area of <italic>MTA2</italic>)</p></td><td>[<xref ref-type="bibr" rid="CR102">102</xref>]</td></tr><tr><td rowspan="2"><italic>NEAT1</italic></td><td>Up-regulated</td><td>HIF-2&#x003b1; dependent</td><td>Non-small cell lung cancer (NSCLC)</td><td><p>&#x02022; Up-regulated in NSCLC</p><p>&#x02022; Associated with TNM stage and metastasis</p></td><td><p>Cell proliferation &#x02191;</p><p>Migration and invasion &#x02191;</p></td><td>miR-101-3p</td><td>SOX9/Wnt/&#x003b2;-catenin signaling pathway</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-101-3p-mediated repression of SOX9/Wnt/&#x003b2;-catenin signaling pathway)</p></td><td>[<xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td>Up-regulated</td><td>HIF-2&#x003b1; dependent &#x00026; preference</td><td>Breast cancer</td><td>High expression of <italic>NEAT1</italic> is associated with poor survival of breast cancer patients</td><td><p>Proliferation &#x02191;</p><p>Apoptosis &#x02193;</p><p>Clonogenic survival &#x02191;</p><p>Paraspeckle formation &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Complex scaffold</bold></p><p>(Induces paraspeckle formation, thereby enhancing cancer cell survival in hypoxia)</p></td><td>[<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR104">104</xref>&#x02013;<xref ref-type="bibr" rid="CR106">106</xref>]</td></tr><tr><td><p><italic>NDRG-OT1</italic></p><p><italic>(lnc-NDRG1-1)</italic></p></td><td>Up-regulated</td><td>N.D.</td><td>Breast cancer</td><td>&#x02022; N.D.</td><td>N.D.</td><td>NDRG1</td><td>NDRG1 degradation</td><td><p><bold>Post-Translational modification</bold></p><p>(<italic>NDRG-OT1</italic> could promote NDRG1 degradation via ubiquitin-mediated proteolysis)</p></td><td>[<xref ref-type="bibr" rid="CR107">107</xref>]</td></tr><tr><td><italic>NORAD</italic></td><td>Up-regulated</td><td>N.D.</td><td>Pancreatic cancer (PC)</td><td><p>&#x02022; Upregulated in PC</p><p>&#x02022; Correlated with shorter overall survival</p></td><td><p>Migration &#x02191;</p><p>Invasion &#x02191;</p><p>EMT &#x02191;</p><p>Metastasis &#x02191;</p></td><td>miR-125a-3p</td><td>The expression of RhoA</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-125a-3p-mediated repression of RhoA)</p></td><td>[<xref ref-type="bibr" rid="CR108">108</xref>]</td></tr><tr><td><p><italic>NUTF2P3-001</italic></p><p><italic>(NUTF2P3)</italic></p></td><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Pancreatic cancer</td><td><p>&#x02022; Upregulated in pancreatic cancer</p><p>&#x02022; A positive correlation between NUTF2P3 and KRAS</p><p>&#x02022; Associated with tumor stage and prognosis</p></td><td><p>Cell viability, proliferation &#x02191;</p><p>Invasion &#x02191;</p><p>KRAS expression &#x02191;</p><p>Metastasis &#x02191;</p></td><td>miR-3923</td><td>The expression of KRAS</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-3923-mediated repression of KRAS)</p></td><td>[<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td><italic>PCGEM1</italic></td><td>Up-regulated</td><td>N.D.</td><td>Gastric cancer (GC)</td><td>Up-regulated in GC</td><td>Invasion and metastasis &#x02191;</td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(Partially through regulating SNAI1, a key transcription factor of EMT)</p></td><td>[<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td rowspan="5"><italic>PVT1</italic></td><td>N.D.</td><td>N.D.</td><td>Nasopharyngeal carcinoma (NPC)</td><td><p>&#x02022; Up-regulated in NPC</p><p>&#x02022; Up-regulation is associated with a poor prognosis in NPC patients</p></td><td><p>NPC cell proliferation &#x02191;</p><p>Colony formation &#x02191;</p><p>In vivo tumorigenesis &#x02191;</p></td><td>KAT2A (chromatin modification factor)</td><td>Transcription of <italic>NF90</italic> (RNA-binding protein)</td><td><p><bold>Epigenetic regulation</bold></p><p>(<italic>PVT1</italic> serves as a scaffold for KAT2A, which mediates H3K9 acetylation, recruiting the nuclear receptor binding protein TIF1&#x003b2; to activate <italic>NF90</italic> transcription, thereby increasing HIF-1&#x003b1; mRNA stability)</p></td><td>[<xref ref-type="bibr" rid="CR111">111</xref>]</td></tr><tr><td>N.D.</td><td>N.D.</td><td>Hepatocellular carcinoma (HCC)</td><td>Up-regulated in HCC tissues and cell lines</td><td><p>Cell proliferation &#x02191;</p><p>Migration &#x02191;</p><p>Invasion and iron uptake &#x02191;</p><p>Apoptosis &#x02193;</p></td><td>miR-150</td><td>The expression of HIG2 (Hypoxia-inducible protein 2)</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-150-mediated repression of HIG2)</p></td><td>[<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td>N.D.</td><td>N.D.</td><td>Gastric cancer</td><td><p>&#x02022; Upregulated in GC tissues and cell lines</p><p>&#x02022; High expression levels correlated with advanced tumor stage and lymph node metastasis</p></td><td><p>GC cell proliferation &#x02191;</p><p>GC cell invasion &#x02191;</p></td><td>miR-186</td><td>The expression of HIF-1&#x003b1;</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-186-mediated repression of HIF-1&#x003b1; expression)</p></td><td>[<xref ref-type="bibr" rid="CR113">113</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Non-small cell lung cancer (NSCLC)</td><td><p>&#x02022; Up-regulated in HIF-1&#x003b1; high group compared with HIF-1&#x003b1; low group</p><p>&#x02022; Negatively correlated with miR-199a-5p expression in NSCLC tissues</p></td><td>Cell proliferation &#x02191;</td><td>miR-199a-5p</td><td>The expression of HIF-1&#x003b1;</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-199a-5p-mediated repression of HIF-1&#x003b1; expression)</p></td><td>[<xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td><p>Up-regulated</p><p>treatment of hypoxia mimetic CoCl<sub>2</sub>)</p></td><td>N.D.</td><td>Cervical Cancer</td><td><p>&#x02022; Up-regulated in Cervical cancer</p><p>&#x02022; Correlates with poorer overall survival</p></td><td><p>Cell proliferation &#x02191;</p><p>Migration and invasion &#x02191;</p><p>Apoptosis &#x02193;</p><p>Cisplatin resistance &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(Possible involvement of the interaction with nucleolin)</p></td><td>[<xref ref-type="bibr" rid="CR115">115</xref>]</td></tr><tr><td><p><italic>RERT-lncRNA</italic></p><p><italic>(RAB4B-EGLN2)</italic></p></td><td>N.D.</td><td>N.D.</td><td><p>Hepatocellular carcinoma</p><p>(HCC)</p></td><td>The expression levels of <italic>RERT-lncRNA</italic> and <italic>EGLN2</italic> were significantly correlated in HCC</td><td><italic>EGLN2</italic> expression &#x02191;</td><td>N.D.</td><td>N.D.</td><td><p><bold>Transcriptional regulation</bold></p><p>(<italic>RERT-lncRNA</italic> induces <italic>EGLN2/PHD1</italic> expression at the transcriptional level)</p></td><td>[<xref ref-type="bibr" rid="CR116">116</xref>]</td></tr><tr><td><italic>UBE2CP3</italic></td><td>N.D.</td><td>N.D.</td><td>Hepatocellular carcinoma (HCC)</td><td><p>&#x02022; Up-regulated in HCC, especially in high EV (endothelial vessel) density tissues</p><p>&#x02022; UBE2CP3 expression combined with EV density is associated with HCC patient prognosis</p></td><td><p>Proliferation &#x02191;</p><p>Migration &#x02191;</p><p>Tube formation &#x02191;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(May partially through UBE2CP3-induced increase in the secretion of VEGFA into the supernatant via activation of the ERK/HIF-1&#x003b1; signaling pathway)</p></td><td>[<xref ref-type="bibr" rid="CR117">117</xref>]</td></tr><tr><td rowspan="5"><italic>UCA1</italic></td><td>Up-regulated</td><td>HIF-1&#x003b1;-dependent</td><td>Estrogen receptor (ER)-positive breast cancer</td><td>N.D.</td><td>Tamoxifen resistance &#x02191;</td><td>miR-18a</td><td>The expression of HIF-1&#x003b1;</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-18a-mediated repression of HIF-1&#x003b1; expression)</p></td><td>[<xref ref-type="bibr" rid="CR118">118</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Hypoxia-resistant gastric cancer (HRGC)</td><td>Upregulated in HRGC cells</td><td>Migration &#x02191;</td><td>miR-7-5p</td><td>The expression of EGFR</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-7-5p-mediated repression of EGFR)</p></td><td>[<xref ref-type="bibr" rid="CR119">119</xref>]</td></tr><tr><td>Up-regulated</td><td>N.D.</td><td>Acute myeloid leukemia (AML)</td><td>Upregulated following ADR (adriamycin)-based chemotherapy</td><td><p>Cytotoxic effect of ADR &#x02193;</p><p>HIF-1&#x003b1;-dependent glycolysis &#x02191;</p></td><td>miR-125a</td><td>The expression of HK2</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-125a-mediated repression of HK2)</p></td><td>[<xref ref-type="bibr" rid="CR120">120</xref>]</td></tr><tr><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(2 HREs)</p></td><td>Bladder cancer</td><td><p>&#x02022; Upregulated in bladder cancer</p><p>&#x02022; <italic>UCA1</italic> expression associated with the clinical stage and histologic grade of bladder cancer</p></td><td><p>Cell proliferation under hypoxia &#x02191;</p><p>Invasion &#x00026; migration under hypoxia &#x02191;</p><p>Apoptosis under hypoxia &#x02193;</p></td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(<italic>UCA1</italic> could modulate the expression of several genes involved in tumorigenic potential, drug resistance and embryonic development)</p></td><td>[<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td>Up-regulated</td><td><p>HIF-1&#x003b1; dependent</p><p>(1 HRE identified)</p></td><td>Osteosarcoma</td><td>N.D.</td><td>Cell growth &#x02191;</td><td>N.D.</td><td>N.D.</td><td><p><bold>Unclear mechanism</bold></p><p>(May partially through inactivating the PTEN/AKT signaling pathway)</p></td><td>[<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td><italic>WT1-AS</italic></td><td>Up-regulated</td><td><p>HIF-1 dependent</p><p>(DNA demethylation of the CpG island)</p></td><td>Myeloid Leukemia</td><td><p>&#x02022; Upregulated in Wilms&#x02019; tumors</p><p>&#x02022; Aberrant WT1-AS splicing often found in acute myeloid leukemia</p></td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td><p><bold>Epigenetic regulation</bold></p><p>(<italic>WT1-AS</italic> mediates hypoxia-induced <italic>WT-1</italic> mRNA upregulation through modulating histone methylation)</p></td><td>[<xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]</td></tr><tr><td><italic>ZEB2-AS1</italic></td><td>Up-regulated</td><td>HIF-1&#x003b1; dependent</td><td><p>Gastric cancer</p><p>(GC)</p></td><td><p>&#x02022; Upregulated in GC</p><p>&#x02022; Correlated with poor differentiation, lymph node metastasis and distant metastasis</p></td><td><p>Cell proliferation and growth &#x02191;</p><p>Invasion &#x02191;</p><p>In vivo tumor growth &#x02191;</p></td><td>miR-143-5p</td><td>The expression of HIF-1&#x003b1;</td><td><p><bold>Sequestration of miRNAs</bold></p><p>(Down-regulation of miR-143-5p-mediated repression of HIF-1&#x003b1; expression)</p></td><td>[<xref ref-type="bibr" rid="CR126">126</xref>]</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: <italic>CRC</italic> colorectal cancer, <italic>CSC</italic> cancer stem cell, <italic>EMT</italic> epithelial&#x02013;mesenchymal transition, <italic>GC</italic> Gastric cancer, <italic>HCC</italic> hepatocellular cancer, <italic>HRE</italic> hypoxia response element, <italic>HUVECs</italic> human umbilical vein endothelial cells, <italic>ICC</italic> Immunocytochemistry, <italic>LC</italic> lung cancer, <italic>M-GSCs</italic> Mesenchymal glioblastoma multiforme stem-like cells, <italic>N.D.</italic> Not determined, <italic>NSCLC</italic> non-small cell lung carcinoma, <italic>OSCC</italic> Oral squamous cell carcinoma, <italic>PDAC</italic> pancreatic ductal adenocarcinoma, <italic>RCC</italic> Renal Cell Carcinoma, <italic>RNP</italic> ribonucleic protein, <italic>TNM</italic> tumor, node, metastasis, <italic>VHL</italic> von Hippel-Lindau protein, <italic>WHO</italic> World Health Organization</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec3"><title>Review</title><sec id="Sec4"><title>LncRNAs as emerging driving forces in cancer progression upon tumor hypoxia</title><p id="Par48">Given the pivotal roles of lncRNA in hypoxia-associated tumorigenesis pathways, multiple approaches have been applied in the identification of hypoxia-regulated lncRNAs [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. A comprehensive analysis coupling RNA-seq with ChIP-seq [<xref ref-type="bibr" rid="CR12">12</xref>] revealed the extensive involvement of HIF-1&#x003b1; and HIF-2&#x003b1; in the transcriptional regulation of lncRNAs upon hypoxia. In recent years, the rapid expansion of research on lncRNAs has provided additional insights into those associated with cellular hypoxia response. Table <xref rid="Tab1" ref-type="table">1</xref> presents an updated list of these hypoxia-associated lncRNAs (HALs). Upon hypoxia, most HALs are up-regulated. HIF could directly promote the expression of these hypoxia-inducible lncRNAs through binding to the HREs (hypoxia response elements) located in their promoter (Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR41">41</xref>]. <italic>lncRNA-LET</italic> [<xref ref-type="bibr" rid="CR93">93</xref>], <italic>CF129</italic> [<xref ref-type="bibr" rid="CR54">54</xref>] and <italic>CRPAT4</italic> [<xref ref-type="bibr" rid="CR56">56</xref>] are among the few which are down-regulated in hypoxic conditions. Notably, <italic>lncRNA-SARCC</italic> is able to respond to hypoxic stress differentially in a VHL-dependent manner [<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par49">Most of the HALs identified have impacts on cancer progression, although the mechanistic details are not all clear. Table <xref rid="Tab1" ref-type="table">1</xref> shows an overview of the tumor HALs. We summarize in the table, their potential molecular target related to hypoxic responses as well as their reported functions and signaling pathways. These HALs may also have hypoxia-independent functions. For the sake of conciseness, those targets are not included in the table. In addition, some of these lncRNAs can be captured by exosomes and transmitted to tumor microenvironment to exert their functions and further propagate the hypoxic responses (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Notably, several HALs, such as <italic>UCA1</italic>, <italic>PVT1</italic>, <italic>H19</italic> and <italic>MALAT1</italic>, might adapt more than one action mode in different cancer types. In the discussion below, we highlight the selected few HALs to illustrate their mechanisms of actions.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>| HALs identified extracellularly</p></caption><table frame="hsides" rules="groups"><thead><tr><th>LncRNA</th><th>Extracellular space identified</th><th>Cell to Cell Transfer</th><th>Functional Impact</th><th>Mechanism</th><th>Ref</th></tr></thead><tbody><tr><td><p><italic>aHIF</italic></p><p>(<italic>HIF1A-AS2</italic>)</p></td><td><p>Serum</p><p>(aHIF level in serum correlates with its expression in matched ectopic endometria)</p></td><td>Endometriotic cyst stromal cells (ECSCs)-derived exosomes to human umbilical vein endothelial cells (HUVECs)</td><td>Elicits proangiogenic behavior in HUVECs, thus facilitating endometriosis angiogenesis.</td><td>Activates VEGF-A, VEGF-D, and b-FGF in HUVECs</td><td>[<xref ref-type="bibr" rid="CR133">133</xref>]</td></tr><tr><td><italic>CCAT2</italic></td><td>Exosomes secreted from cultured glioma cells</td><td>U87-MG glioma cells to HUVECs</td><td>Promotes HUVEC angiogenesis and inhibits apoptosis induced by hypoxia</td><td>Promotes VEGF-A, TGF-&#x003b2; and Bcl2 expression. Inhibits BAX and caspase 3 expression</td><td>[<xref ref-type="bibr" rid="CR134">134</xref>]</td></tr><tr><td><italic>HISLA</italic> (<italic>LINC01146</italic>)</td><td>Extracellular vesicles secreted by tumor associated fibroblasts (TAMs)</td><td>TAMs to breast cancer cells</td><td>Enhances aerobic glycolysis and apoptotic resistance of cancer cells</td><td>Stabilizes HIF-1&#x003b1;</td><td>[<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td><italic>PVT1</italic></td><td>Exosomes secreted from cultured colon cancer cells. Cancer cells with more aggressive phenotypes have more extracellular <italic>PVT1</italic></td><td>Not determined</td><td>Promotes cell proliferation and inhibits apoptosis.</td><td/><td>[<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td><italic>linc-ROR</italic></td><td>Exosomes secreted from cultured hepatocellular carcinoma cells</td><td>HCC cancer cells to cancer cells</td><td>Promotes cell survival of recipient cells</td><td>Through a miR-145&#x02013;HIF-1&#x003b1; signaling module to increase HIF-1&#x003b1; expression</td><td>[<xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td><italic>UCA1</italic></td><td>Exosomes secreted from cultured bladder cancer cells &#x00026; serum</td><td>Bladder cancer 5637 cells with high expression of UCA1 to bladder cancer UMUC2 cells with low expression of UCA1</td><td><p>Promotes cell proliferation, migration and invasion of recipient cells</p><p>Promotes xenograft growth</p></td><td>Through regulating the expression of genes involved in EMT (E-cad, MMP9, vimentin)</td><td>[<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr></tbody></table></table-wrap></p><sec id="Sec5"><title>HAL-mediated epigenetic and transcriptional regulation</title><p id="Par50">A large number of lncRNAs are localized in the nucleus, participating in various biological processes, including chromatin organization, nuclear structure, transcriptional and post-transcriptional regulation of gene expression. With regard to chromatin organization, the pangenomic investigations of RNA&#x02013;protein interactions have shown that two hypoxia-inducible, oncogenic antisense RNAs <italic>ANRIL</italic> (also known as CDKN2B antisense RNA 1) and <italic>HOTAIR</italic> (HOX transcript antisense RNA) [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR80">80</xref>] could interact with different histone-modifying complexes, and have thus been proposed to impact the chromatin modification and transcriptional state [<xref ref-type="bibr" rid="CR138">138</xref>]. However, whether these two antisense RNAs are involved in modulating gene expression in response to hypoxia via epigenetic modification or chromatin re-organization remains to be characterized. In addition, <italic>WT1-AS</italic> could mediate hypoxia-induced upregulation of oncogenic transcription factor WT-1 <italic>in cis</italic> through modulating histone H3K4 and H3K9 methylation around the transcription start site of <italic>WT1</italic> mRNA, contributing to acute myeloid leukemia (AML) progression [<xref ref-type="bibr" rid="CR124">124</xref>]. Similarly, in gastric cancer, <italic>lncRNA-AK058003</italic>, which could be profoundly induced by hypoxia, resides upstream of <italic>SNCG</italic> (synuclein gamma, a synuclein family member, promotes migration, invasion and metastasis) and enhances <italic>SNCG</italic> expression <italic>in cis</italic> through demethylation of <italic>SNCG</italic> promoter CpG islands, thereby driving hypoxia-induced metastasis [<xref ref-type="bibr" rid="CR90">90</xref>]. In the context of nasopharyngeal carcinoma (NPC), up-regulated <italic>PVT1</italic> could serve as a scaffold for a transcriptional activator, the histone acetyltransferase KAT2A, to activate transcription of <italic>NF90</italic>. NF90, a RNA-binding protein, has been reported to stabilize many target mRNAs, including <italic>HIF1A</italic> mRNA. Indeed, the upregulated NF90 increased <italic>HIF1A</italic> mRNA stability and promoted malignant transformation of NPC cells [<xref ref-type="bibr" rid="CR111">111</xref>]. In addition, in hypoxia-injured pheochromocytoma cells, up-regulated <italic>MEG3</italic> (maternally expressed gene 3) could recruit methylation proteins DNMT3a, DNMT3b and MBD1 to facilitate <italic>TIMP2</italic> promoter methylation, which in turn inhibited the expression of this cell cycle arrest inducer TIMP2. Moreover, a HIF-1&#x003b1; negative regulator, OS-9, is reported to facilitate HIF-1&#x003b1; hydroxylation and subsequent proteasomal degradation through tethering the interaction between HIF-1&#x003b1; and prolyl hydroxylases (PHDs) [<xref ref-type="bibr" rid="CR139">139</xref>]. Interestingly, in pancreatic ductal adenocarcinoma (PDAC), another lncRNA <italic>ENST00000480739</italic> could inhibit HIF-1&#x003b1; by up-regulating <italic>OS9</italic> (osteosarcoma amplified-9) expression through enhancing the acetylation of H3K27 within <italic>OS9</italic> gene promoter [<xref ref-type="bibr" rid="CR60">60</xref>]. Of note, in PDAC, the level of <italic>ENST00000480739</italic> is markedly downregulated, and negatively correlated with lymph node metastasis, in agreement with its negative regulatory role in HIF-1 signaling [<xref ref-type="bibr" rid="CR60">60</xref>]. As <italic>ENST00000480739</italic> resides upstream of the <italic>OS9</italic> promoter region, this lncRNA also act <italic>in cis</italic> to induce <italic>OS9</italic> transcription.</p><p id="Par51">Apart from chromatin structure remodeling, a series of HALs could modulate transcription and thereby fine-tune the HIF network. For instance, lncRNA <italic>HIF2PUT</italic> (HIF-2&#x003b1; promoter upstream transcript), <italic>RERT-lncRNA</italic> and hypoxia-inducible <italic>BC005927</italic> are all found to act <italic>in cis</italic> to up-regulate neighboring protein-coding genes <italic>HIF2A</italic> (encodes HIF-2&#x003b1;), <italic>EGLN2</italic> (encodes prolyl hydroxylase PHD1) and <italic>EPHB4</italic> (encodes Ephrin type-B receptor 4, a metastasis-related gene), at the transcriptional level, respectively [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR116">116</xref>].</p><p id="Par52">Moreover, HALs could directly act on specific transcription factors through physical interactions to modulate their transactivation activities. We recently identified a hypoxia-inducible lncRNA <italic>LncHIFCAR</italic> (long noncoding HIF-1&#x003b1; co-activating RNA, also known as <italic>MIR31HG</italic>) acting as a HIF-1&#x003b1; co-activator via direct interaction with HIF-1&#x003b1;, thereby enhancing the binding of HIF-1&#x003b1; and cofactor p300 to the target loci (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b). As the abundance of the HIF complex increases, the hypoxia-induced HIF-1 signaling cascade is augmented to further promote subsequent cancer progression [<xref ref-type="bibr" rid="CR89">89</xref>]. Meanwhile, in pancreatic cancer, HIF-1&#x003b1;-induced lncRNA<italic>-MTA2TR</italic> (MTA2 transcriptional regulator RNA) transcriptionally up-regulates the expression of oncogenic MTA2 (metastasis associated protein 2) by recruiting ATF3 (activating transcription factor 3) to the promoter area of <italic>MTA2</italic> [<xref ref-type="bibr" rid="CR102">102</xref>]. Subsequently, MTA2 can enhance the accumulation of HIF-1&#x003b1; protein via MTA2-mediated HIF-1&#x003b1; deacetylation and stabilization, which further activates HIF-1&#x003b1; transcriptional activity, forming feedback loops to augment HIF-1 signaling [<xref ref-type="bibr" rid="CR102">102</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>c). In addition, through binding to PSF (PTB-associated splicing factor), hypoxia-induced lncRNA <italic>MALAT1</italic> released PSF from its downstream proto-oncogene <italic>GAGE6</italic> (proto-oncogene G antigen 6) and activated its transcription, thereby promoting proliferation, migration and invasion of lung adenocarcinoma cells [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Given the extraordinary variety of transcriptional regulatory machinery discovered in the cell, it is anticipated that more lncRNAs-mediated regulation on hypoxia-induced transcriptional program will be unraveled in the imminent future.</p></sec><sec id="Sec6"><title>HAL-mediated post-transcriptional control</title><p id="Par53">HALs also participate in post-transcriptional regulation including mRNA stability and miRNA-mediated gene silencing.</p><sec id="FPar1"><title>mRNA stability control</title><p id="Par54">Three HALs, <italic>lncRNA-LET</italic> (Long noncoding RNA Low Expression in Tumor), <italic>DANCR</italic> (Differentiation Antagonizing Non-Protein Coding RNA) and <italic>HIF1A-AS2</italic> (HIF1A Antisense RNA 2; also known as <italic>aHIF</italic>), have all been reported to affect <italic>HIF1A</italic> mRNA stability. <italic>lncRNA-LET</italic> expression is generally suppressed in various types of tumors, whereas hypoxia-induced HDAC3 (histone deacetylase 3) could repress its expression by reducing the histone acetylation of the <italic>lncRNA-LET</italic> promoter region [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. Mechanistically, <italic>lncRNA-LET</italic> is bound to NF90 (nuclear factor 90), which increases NF90 degradation by the proteasome. As RNA binding protein NF90 could stabilize <italic>HIF1A</italic> mRNA [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR141">141</xref>], the downregulation of <italic>lncRNA-LET</italic> upon hypoxia plays a key role in the stabilization of NF90 protein, thereby increasing <italic>HIF-1A</italic> mRNA stability upon hypoxia and accordingly hypoxia-induced cancer cell invasion [<xref ref-type="bibr" rid="CR93">93</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>d). Likewise, in nasopharyngeal carcinoma, another oncogenic lncRNA <italic>DANCR</italic> was up-regulated and associated with lymph lode metastasis and poor survival [<xref ref-type="bibr" rid="CR57">57</xref>]. Through interaction with the NF90/NF45 complex, <italic>DANCR</italic> could increase <italic>HIF1A</italic> mRNA stability, leading to metastasis and disease progression.</p><p id="Par55">In addition, another hypoxia-inducible antisense lncRNA <italic>HIF1A-AS2</italic>, was shown to be up-regulated in various tumors [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>] and could differentially regulate HIF-1&#x003b1; and HIF-2&#x003b1; expression during long-term hypoxic conditions [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Upon acute hypoxia, HIF-1&#x003b1; and HIF-2&#x003b1; were similarly induced. Interestingly, during prolonged hypoxia, these two proteins were differentially regulated as HIF-1&#x003b1; protein level gradually decreased due to a reduction in its mRNA stability, whereas HIF-2&#x003b1; protein remained upregulated. Meanwhile, long-term hypoxia also induced an increase in <italic>HIF1A-AS2</italic>, whose gene promoter harbors functional HREs. During prolonged hypoxia, <italic>HIF1A-AS2</italic> could bind to its sense counterpart, the <italic>HIF-1A</italic> mRNA 3&#x02032;-UTR, and possibly expose the AU-rich elements in this region, thereby destabilizing <italic>HIF-1A</italic> mRNA to convey target gene specificity [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Paradoxically, <italic>HIF1A-AS2</italic> was also shown to sequester miR153-3p (see next section) to enhance <italic>HIF-1A</italic> expression [<xref ref-type="bibr" rid="CR44">44</xref>]. Thus, the mode of action of <italic>HIF1A-AS2</italic> is complex and likely context-dependent.</p></sec><sec id="FPar2"><title>miRNA sponges</title><p id="Par56">A wealth of lncRNAs adapt a well-characterized, common mechanism, &#x0201c;ceRNA (competing endogenous RNA)&#x0201d; or &#x0201c;RNA sponges&#x0201d;, to repress miRNA-mediated gene silencing. The ceRNAs compete for shared miRNAs, sequester these miRNAs and diminish their silencing effect on target mRNAs.</p><p id="Par57">Functional manipulations have demonstrated that several HALs, such as <italic>lincRNA-ROR</italic> [<xref ref-type="bibr" rid="CR87">87</xref>]<italic>, PVT1</italic> [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]<italic>, HIF1A-AS2</italic> [<xref ref-type="bibr" rid="CR44">44</xref>]<italic>, UCA1</italic> [<xref ref-type="bibr" rid="CR118">118</xref>]<italic>, HOTAIR</italic> [<xref ref-type="bibr" rid="CR79">79</xref>]<italic>, FEZF1-AS1</italic> [<xref ref-type="bibr" rid="CR63">63</xref>]<italic>, ZEB2-AS1</italic> [<xref ref-type="bibr" rid="CR126">126</xref>] <italic>and H19</italic> [<xref ref-type="bibr" rid="CR66">66</xref>]<italic>,</italic> could act as a &#x02018;ceRNA&#x02019; to reduce individual specific miRNA-mediated <italic>HIF1A</italic> mRNA destabilization and thereby restoring HIF-1&#x003b1; levels and consequently promote cancer progression (Table <xref rid="Tab1" ref-type="table">1</xref>). Specifically, in breast cancer stem cells, by absorbing endogenous miRNA let-7 and aborting let-7-mediated <italic>HIF1A</italic> mRNA suppression, hypoxia-induced H19 could stimulate HIF-1&#x003b1; expression [<xref ref-type="bibr" rid="CR66">66</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>e). In addition, in glioblastoma, hypoxia-induced H19 up-regulation has been shown to confer an aggressive behavior by sequestering miR-181d and nullifying its suppression on an oncogenic EMT-associated factor, &#x003b2;-catenin [<xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par58">In a similar way, certain HALs could act as a ceRNA to modulate other hypoxia-responsive regulators than HIF-1&#x003b1;. In gastric cancer, <italic>GAPLINC</italic> (Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA) is a HIF-1&#x003b1; direct, transcriptional downstream target, and could promote invasive tumor progression [<xref ref-type="bibr" rid="CR64">64</xref>]. Mechanistically, <italic>GAPLINC</italic> could serve as a decoy for miR-211-3p to restore the levels of cancer stem cell marker CD44, enhancing tumor progression [<xref ref-type="bibr" rid="CR65">65</xref>]. Aside from <italic>GAPLINC</italic>, <italic>NORAD</italic> [<xref ref-type="bibr" rid="CR108">108</xref>]<italic>, UCA1</italic> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]<italic>, HOTTIP</italic> [<xref ref-type="bibr" rid="CR82">82</xref>]<italic>, EIF3J-AS1</italic> [<xref ref-type="bibr" rid="CR59">59</xref>]<italic>, MALAT1</italic> [<xref ref-type="bibr" rid="CR100">100</xref>]<italic>, FAM201A</italic> [<xref ref-type="bibr" rid="CR62">62</xref>]<italic>, AGAP2-AS1</italic> [<xref ref-type="bibr" rid="CR49">49</xref>]<italic>, LINC01436</italic> [<xref ref-type="bibr" rid="CR84">84</xref>]<italic>, NEAT1</italic> [<xref ref-type="bibr" rid="CR103">103</xref>]<italic>, NUTF2P3</italic> [<xref ref-type="bibr" rid="CR109">109</xref>] lncRNAs were shown to function in this way (Table <xref rid="Tab1" ref-type="table">1</xref>). Collectively, in response to hypoxia, the crosstalk among the lncRNA and miRNA transcriptomes build a reciprocal repression feedback network, eliciting concordant shift to transcriptional reprogram. Further exploration of this pertinent co-working group of lncRNAs and miRNAs under hypoxic conditions would help appreciate this emerging additional layer of post-transcriptional regulation governed by HALs.</p></sec></sec><sec id="Sec7"><title>HAL-mediated control of protein activity, stability and/or higher-order complex formation</title><p id="Par59">In addition to acting as ceRNAs to modulate gene expression through interaction with miRNAs, HALs have multiple molecular modes to act at the protein level to further modulate gene expression. One of the hypoxia-induced lncRNAs, <italic>PVT1</italic> (plasmacytoma variant translocation 1), was implicated in cervical cancer progression, likely through its interaction with a multifunctional shuttling protein, nucleolin [<xref ref-type="bibr" rid="CR115">115</xref>]. In multiple cancer cell lines, HIF-1-induced <italic>lincRNA-p21</italic> provides another example as to how HALs modulate hypoxia response by protein sequestration. Through separate binding to HIF-1&#x003b1; and VHL, <italic>lincRNA-p21</italic> could increase HIF-1&#x003b1; accumulation by disruption of the VHL/HIF-1&#x003b1; interaction and subsequent attenuation of VHL-mediated HIF-1&#x003b1; ubiquitination and degradation [<xref ref-type="bibr" rid="CR85">85</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>f). Another HIF-1&#x003b1; binding lncRNA <italic>CASC9</italic> (cancer susceptibility candidate 9) is highly expressed in nasopharyngeal carcinoma (NPC) tissues. <italic>CASC9</italic> could interact with and stabilize HIF-1&#x003b1;, promoting the glycolysis and tumorigenesis of NPC cells [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par60">Nevertheless, in addition to fine-tuning the activity of one single protein, HALs can also dynamically modulate higher-order protein organizations by serving as scaffolds or molecular decoys. In mesenchymal glioblastoma stem-like cells, through direct binding to two RNA binding proteins, DHX9 (ATP-dependent RNA helicase A) and IGF2BP2 (insulin-like growth factor 2 mRNA-binding protein 2), lncRNA <italic>HIF1A-AS2</italic> could facilitate the interaction between this protein complex and their mRNA target <italic>HMGA1</italic> (high mobility group AT-hook 1), thereby enhancing <italic>HMGA1</italic> expression as well as the downstream molecular response to hypoxic stress [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par61">In triple-negative breast cancer (TNBC), <italic>LINK-A</italic> (long intergenic non-coding RNA for kinase activation) has a critical role in the growth factor-induced HIF-1&#x003b1; signaling under normoxic conditions [<xref ref-type="bibr" rid="CR88">88</xref>]. <italic>LINK-A</italic> is required for the recruitment of BRK (breast tumor kinase) and subsequent enzymatic activation, which is stimulated by HB-EGF (Heparin-binding EGF-like growth factor) signal. HB-EGF mediates the heterodimerization of EGFR (epidermal growth factor receptor) and GPNMB (transmembrane glycoprotein NMB) to form &#x02018;EGFR:GPNMB&#x02019; complex. Due to its direct interaction with BRK and LRRK2 (leucine-rich repeat kinase 2), <italic>LINK-A</italic> could recruit these two kinases to EGFR:GPNMB heterodimer, thereby inducing their kinase activities, resulting in HIF-1&#x003b1; phosphorylation: BRK-mediated HIF-1&#x003b1; phosphorylation at Tyr<sup>565</sup>, a phosphorylation preventing the adjacent Pro<sup>564</sup> hydroxylation of HIF-1&#x003b1; and subsequent HIF-1&#x003b1; degradation under normoxic conditions; and LRRK2-mediated HIF-1&#x003b1; phosphorylation at Ser<sup>797</sup>, which facilitates the interaction of HIF-1&#x003b1; with the transcriptional cofactor p300 [<xref ref-type="bibr" rid="CR88">88</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>g). In TNBC samples, both <italic>LINK-A</italic> abundance and HIF-1 signaling activation are correlated with cancer progression and shorter survival, revealing potential therapeutic targets for TNBC [<xref ref-type="bibr" rid="CR88">88</xref>].</p><p id="Par62">An additional novel function of lncRNAs is their structural role in the assembly of nuclear domains. For instance, <italic>MALAT1</italic> (metastasis-associated lung adenocarcinoma transcript&#x000a0;1, also known as <italic>NEAT2</italic>) and <italic>NEAT1</italic> (nuclear enriched abundant transcript&#x000a0;1) are located in two well-characterized nuclear bodies, nuclear speckles and paraspeckles, respectively. Also known as SC35 splicing domains, nuclear speckles are membrane-less compartments and their formation involves &#x0201c;phase-separation&#x0201d; mediated by aggregated lncRNAs and proteins. Being an abundant component of the nuclear speckles, <italic>MALAT1</italic> associates with numerous splicing factors and other SR (serine/arginine-rich) proteins, and is required for their correct localization to the nuclear speckles, although the overall nuclear speckle assembly is not dependent on the abundance of <italic>MALAT1</italic> [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. So far, the functional involvement of <italic>MALAT1</italic> in RNA splicing in response to hypoxia remains to be determined. In contrast, lncRNA <italic>NEAT1</italic> is shown to be an essential architectural component of nuclear paraspeckles [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. The precise function of paraspeckles remains largely elusive, but proposed to regulate gene expression via the retention of hyper-edited RNA and other multifunctional factors in the nucleus [<xref ref-type="bibr" rid="CR104">104</xref>]. Given the functional involvement of both <italic>MALAT1</italic> and <italic>NEAT1</italic> in nuclear structure, further investigation of the extent to which these nuclear structures and their associated transcription reprogramming respond to hypoxia will deepen our understanding of the cellular dynamic response to hypoxia.</p></sec><sec id="Sec8"><title>HAL-mediated control of hypoxia response via unclear mechanism</title><p id="Par63">As listed in Table <xref rid="Tab1" ref-type="table">1</xref>, most of the HALs identified with profound impact on tumorigenesis have not yet been examined in mechanistic detail. However, other reports regarding the same lncRNA with functional characterization might reveal clues about their biological roles in response to hypoxia. For instance, lncRNA <italic>PCGEM1</italic> was found to be overexpressed in gastric cancer, and could be induced by hypoxia [<xref ref-type="bibr" rid="CR110">110</xref>]. In gastric cancer cells, <italic>PCGEM1</italic> could promote the invasion and metastasis through activating the expression of SNAI1, a key transcription factor of EMT, though the underlying mechanism remains elusive [<xref ref-type="bibr" rid="CR110">110</xref>]. Notably, in prostate cancer, our group previously reported that the oncogenic <italic>PCGEM1</italic> could promote chromatin recruitment of c-Myc and enhances its transactivation activity through direct physical interaction [<xref ref-type="bibr" rid="CR146">146</xref>]. As <italic>SNAI1</italic> is a well-characterized downstream gene of c-Myc, the possible functional role of the <italic>PCGEM1</italic>/c-Myc/SNAI1 signaling axis in hypoxia-associated cancer progression warrants further investigation.</p><p id="Par64">In summary, as noted in the above sections, given the relatively large size and the structural flexibility of lncRNAs, it is to be expected that they interact with multiple RNA or protein components and have multi-functions, perhaps in a context-dependent manner. As such, their roles in hypoxia responses and in tumor progression may differ appreciably in different cancer types.</p></sec></sec><sec id="Sec9"><title>LncRNAs as predictive biomarkers and therapeutic targets for hypoxic tumor</title><sec id="Sec10"><title>Extracellular vesicles-containing HALs and their biologic effects on tumorigenesis</title><p id="Par65">Extracellular vesicles are effective devices for transporting biomolecules among various cells types [<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>]. Based on the difference in size and biogenesis, cell-derived extracellular vesicles can be broadly divided into two main categories: exosomes (30&#x02013;100&#x02009;nm in diameter) and microvesicles. Together with proteins and other non-coding RNAs, emerging evidence has shown that lncRNAs are packaged into exosomes [<xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR150">150</xref>], and the abundance of lncRNAs in exosomes correlates with their expression level in the cell of origin [<xref ref-type="bibr" rid="CR151">151</xref>]. Through exosomal transfer, several lncRNAs are shown to potentiate cell responses to hypoxia between cancer cells [<xref ref-type="bibr" rid="CR87">87</xref>], as well as between cancer cell and the associated microenvironment [<xref ref-type="bibr" rid="CR150">150</xref>]. Table <xref rid="Tab2" ref-type="table">2</xref> summarizes hypoxia-associated lncRNAs identified extracellularly. For example, <italic>linc-ROR</italic> was found abundant in tumor cells as well as in exosomes derived from tumor cells [<xref ref-type="bibr" rid="CR87">87</xref>]. It is increased both in cells or exosomes during hypoxia, and it up-regulates HIF-1&#x003b1; expression by absorbing miR-145. By co-culture systems, <italic>linc-ROR</italic>-containing exosomes increase HIF-1a transcription in recipient cells [<xref ref-type="bibr" rid="CR87">87</xref>]. Hypoxia can shape and fine tune specific macrophage phenotypes in the tumor milieu that are known to promote tumor progression [<xref ref-type="bibr" rid="CR152">152</xref>]. Chen et al found lncRNA <italic>HISLA</italic> (also known as <italic>LINC01146</italic>), secreted by tumor-associated macrophages, stabilized HIF-1&#x003b1; and enhanced aerobic glycolysis in cancer cells, leading to contagious metabolic reprogramming within tumor regions [<xref ref-type="bibr" rid="CR150">150</xref>]. <italic>PVT1</italic>, a lncRNA that often co-amplifies with c-myc and functions as miRNA sponge to upregulate HIF-1&#x003b1; expression [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>], is another example of exosomal transfer between TAMs (tumor associated macrophages) and cancer cells. <italic>PVT1</italic> is detected in exosomes derived from colon cancer cells, particularly in more aggressive cells [<xref ref-type="bibr" rid="CR136">136</xref>]. In granulocytic myeloid-derived suppressor cells (G-MDSCs), <italic>PVT1</italic> was up-regulated by HIF-1&#x003b1; under hypoxia and contributed to immunosuppression, given its depletion reduced the suppression of these cells on T-cells and delayed tumor progression [<xref ref-type="bibr" rid="CR155">155</xref>]. Other exosomal-transferred lncRNAs that are implicated in cancer cells during hypoxia include <italic>UCA1</italic> in bladder cancer for promoting tumor growth and EMT [<xref ref-type="bibr" rid="CR137">137</xref>], and <italic>CCAT2</italic> for glioma&#x02019;s resistance to apoptosis and angiogenesis [<xref ref-type="bibr" rid="CR134">134</xref>].</p><p id="Par66">The functions of lncRNAs in exosomes for tumor progression await to be explored given a significant level of non-coding RNAs are revealed in exosomes (and elevated upon hypoxia) whereas only a small fraction has been studied [<xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. Accordingly, it is conceivable that multiple tumor phenotypes and signaling pathways are affected upon exosomal loading. Indeed, by microarray analyses, Mao et al showed hundreds of lncRNAs, together with other transcripts, are changed in endothelial cell recipients of exosomes derived from squamous cancer cells [<xref ref-type="bibr" rid="CR157">157</xref>]. Importantly, they found exosomes obtained from hypoxic condition facilitate angiogenesis and metastasis better than those obtained from normoxic condition in a xenograft model. Similar effects between normoxic exosomes and hypoxic exosomes on angiogenesis were found in a mouse xenograft model of glioblastoma, with additional effect on accelerating tumor expansion at later stage [<xref ref-type="bibr" rid="CR158">158</xref>]. The elevation in transcripts by exosomes could result from direct gene transfer, or sequential effects mediated by the transferred genes. By which mechanism lncRNAs are selected to be packaged in the exosomes upon stimuli is not known; nevertheless, these studies revealed exosomes as a means by which hypoxia in the tumor microenvironment facilitates tumor cells to spread and progress.</p></sec><sec id="Sec11"><title>Diagnostic potential of HALs</title><p id="Par67">Several HALs with known oncogenic functions have been detected in patient-derived exosomes, including <italic>H19</italic> in serum from patients with bladder cancer [<xref ref-type="bibr" rid="CR159">159</xref>], <italic>HOTAIR</italic> in urinary exosomes from patients with urothelial bladder cancer [<xref ref-type="bibr" rid="CR156">156</xref>], <italic>UCA1</italic> in serum from bladder cancer patients [<xref ref-type="bibr" rid="CR137">137</xref>], and <italic>HIF1A-AS2</italic> in patients with endometriosis [<xref ref-type="bibr" rid="CR133">133</xref>]. Future studies aimed at identifying hypoxia-responsive transcripts in extracellular vesicles would surely reveal more players in this aspect. Bearing differential expression patterns between normal and malignant stages and/or tumor size, oncogenic lncRNAs that can be detected extracellularly would potentially serve as non-invasive biomarkers for early detection, prognosis prediction, and disease surveillance. <italic>PCA3</italic>, up-regulated in &#x0003e;&#x02009;90% of men with prostate cancer, is an example of this [<xref ref-type="bibr" rid="CR160">160</xref>]. A urine-based assay has been approved by the United States Food and Drug Administration (FDA) since 2012 as an alternative diagnostic test for patients undergoing repeat prostate biopsy or with previous negative prostate biopsy.</p><p id="Par68">As described above, there is considerable evidence indicating hypoxia as a progression factor for tumor development [<xref ref-type="bibr" rid="CR161">161</xref>]. Hypoxia promotes angiogenesis, tumor metastasis, immune evasion and therapy-resistance. The oxygenation status of tumor was reported to influence local tumor response to radiation treatment, as well as overall survival in a variety of tumors [<xref ref-type="bibr" rid="CR162">162</xref>&#x02013;<xref ref-type="bibr" rid="CR164">164</xref>]. Chemotherapeutic drugs, such as Docetaxel and Sorafenib, also tend to be more effective in normoxic conditions [<xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR166">166</xref>]. The hypoxic regions in tumors are infiltrated with cells which promote tumor tolerance (regulatory T-cells, myeloid-derived suppressor cells, and macrophages), while antitumor T-cells are devoid and inhibited by HIF-1&#x003b1;-mediated accumulation of extracellular adenosine [<xref ref-type="bibr" rid="CR167">167</xref>&#x02013;<xref ref-type="bibr" rid="CR169">169</xref>]. PD-L1 (Programmed death-ligand 1), a ligand expressed by tumor cells or myeloid-derived suppressor cells to suppress T-cell&#x02019;s anti-tumor immunity, is up-regulated by and a direct target of HIF-1&#x003b1; during hypoxia [<xref ref-type="bibr" rid="CR170">170</xref>]. It has become increasingly apparent that hypoxia in tumors fosters immune suppression and prevents effective immunotherapy. Considering the ill-effects of hypoxia, it is important to detect and to overcome tumor hypoxia even before therapy starts, for the best of patient care.</p><p id="Par69">By far, while there has been a great deal of interest in methodologies to measure hypoxia in patients, an efficient, non-invasive, while sensitive method to detect small regions of hypoxia that frequently occur in the tumors is still lacking [<xref ref-type="bibr" rid="CR163">163</xref>]. A few metabolic markers (HIF-1&#x003b1;, HIF-2, CA9 and GLUT1) have been used to assess low oxygen tensions by immunohistochemistry [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>]; however, the application of them in clinic is limited given that their expressions can be triggered by factors other than hypoxia and that biopsies only represent a small sampling of the tumor. As exosome composition mirrors the hypoxia status of tumors [<xref ref-type="bibr" rid="CR158">158</xref>], a hypoxia signature may be formulated based on the exosomal hypoxia-responsive transcripts including HALs to evaluate oxygenation in the body for clinical exploitation, once our knowledge is advanced.</p></sec><sec id="Sec12"><title>Therapeutic potential of HALs (targeting hypoxia in cancer therapy, a lncRNA perspective)</title><p id="Par70">Several approaches have been proposed to target hypoxia in tumor [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]. These include drugs that induce cell death selectively in hypoxic cells, e.g. hypoxia-activated prodrugs, or drugs sensitizing hypoxic cells to radiation. Since the adaptive response to hypoxia mainly orients from the transactivation of HIF signaling, some approaches seek to block hypoxia-induced responses by targeting HIFs and the related signaling, or to target pathways that also play pivotal roles in hypoxia adaptation, such as signaling involving mTOR, DNA damage response, and the unfolded protein response. In that regard, HALs that are elevated upon hypoxia and contribute to tumor progression in pre-clinical studies could potentially serve as molecular targets, e.g. <italic>PVT</italic>, <italic>LncHIFCAR</italic>, etc. (see Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR41">41</xref>]. By contrast, HALs that are repressed in order to magnify hypoxia response, such as <italic>lncRNA-LET</italic>, could be induced for therapeutic intervention.</p><p id="Par71">Various strategies have been developed to modulate RNAs. Silencing lncRNAs by small interfering RNAs, antisense oligonucleotides (ASOs), or ribozymes and deoxynucleotides are well demonstrated in pre-clinical studies. Until now, three ASOs and one aptamer therapies have been approved by the FDA for diseases and a handful of others are in clinical trials. The development of short oligonucleotides that fold into three-dimensional structures, aptamers, offers a greater specificity as they target specific structure regions to either mediate RNA degradation or disrupt functional interactions between binding partners [<xref ref-type="bibr" rid="CR173">173</xref>]. Small molecules that bind to lncRNA and hinder its interaction surface have similar advantages. Additionally, peptide nucleic acids (PNA)-based approach against lncRNAs have been described. <italic>HOTAIR</italic>-targeting PNAs conjugated with pH-low insertion peptide (pHLIP) successfully delivered the anti-lncRNA to the acidic tumor. It blocked the interaction between <italic>HOTAIR</italic> and EZH2, subsequently inhibited <italic>HOTAIR</italic>-EZH2 activity and re-sensitized resistant ovarian tumors to platinum [<xref ref-type="bibr" rid="CR174">174</xref>].</p><p id="Par72">In any case, an issue all hypoxia-based therapeutics need to consider is the poorly perfused tissue in tumors. In response to their rapid growth, tumor cells secret pro-angiogenic factors such as VEGF to induce vascular formation, yet the constant stimulation leaves tumor vasculature ill-formed and leaky [<xref ref-type="bibr" rid="CR175">175</xref>]. Simultaneous blockade of HIFs and pro-angiogenic factors has been proposed for targeting tumor hypoxia, in that targeting the angiogenic factors may allow vasculature to mature, resulting more effective blood supply and drug delivery. Another strategy is to relieve oxygen demand by drugs that alleviates oxygen tension in tumors. Papaverine, an FDA-approved drug as a smooth muscle relaxant, was found to inhibit mitochondria complex I and enhance the response to radiotherapy, while well-oxygenated normal tissues were not sensitized [<xref ref-type="bibr" rid="CR176">176</xref>]. Accordingly, lncRNAs that regulate mitochondria respiration may be considered for targeting tumor hypoxia as an adjuvant treatment.</p></sec></sec></sec><sec id="Sec13"><title>Conclusion and future perspectives</title><p id="Par73">Decades of intensive scientific research on hypoxia and HIF biology has greatly contributed to our understanding of oxygen homeostasis. Over the past few years, a substantial increase in our knowledge of the noncoding transcriptomes, while putting on an additional layer of complexity in hypoxia regulation and responses, has advanced our comprehension of hypoxic biology. This review has presented an update of our current insights regarding lncRNAs involved in hypoxia-associated processes, highlighting the diverse mechanisms and functions of hypoxia-associated lncRNAs (HALs). These novel action modes unveil the unanticipated predominance of HALs in the regulation of gene expression under hypoxic conditions and outline the elaborate network among the different types of RNA transcripts, chromatin DNA and protein factors. However, advancement in analytical methodologies and in structural and genomic technologies of RNA are required to open up new important directions for in-depth investigation. For the state-of-the-art methodologies to unveil the functions of lncRNAs, readers are directed to two excellent recent reviews [<xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR178">178</xref>], as well as those in this special issue.</p><p id="Par74">The role of HIF in hypoxia responses has been the central topic of most investigations. Indeed, HIF has been shown to be a central regulator of the coding and non-coding transcriptome and tightly associated with cancer risk [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR179">179</xref>&#x02013;<xref ref-type="bibr" rid="CR181">181</xref>]. Most HALs, in particular, are highly responsive to hypoxia and HIF and, in turn, participate in the regulation of the protein-coding genome either <italic>in cis</italic> or <italic>in trans</italic> to offer multiple routes to HIF-mediated gene regulation, implementing both positive and negative feedback loops that either strengthen or repress the hypoxia response. Most notably, the extracellular vesicles-containing HALs could evoke peculiar response to specific cell population, affecting nearby cells and those at a great distance, diversifying the hypoxia response far beyond the previously recognized. The cellular adaptation to hypoxia requires the precisely coordinated regulatory network to cope with the acute, transient and dynamic oxygen deprivation stress in local regions, whereas lncRNAs, with their flexible structure for interaction and quick biogenesis nature, could be uniquely suited to provide rapid, precise and reversible responses to this insult. It is clear that HALs and their downstream targets are shown to confer a series of biological effective responses to hypoxia. Feasibly, this extensive molecular crosstalk between lncRNA and hypoxic signaling cascades may undergo co-evolution to maintain such an exquisite, orchestrated program. Thus, for a comprehensive understanding of hypoxia-associated tumor biology, it is of relevance to characterize the long non-coding transcriptome involved in hypoxia adaptation.</p><p id="Par75">Given the prominent pathological roles of HALs in hypoxia-associated cancer progression, these RNAs could be exploited as useful indicators to define the cancer intrinsic subtypes to aid in precision medicine. Importantly, HALs are often tissue specific and respond to hypoxia in a cell context dependent manner. As such, they are excellent markers for tissue and tumor hypoxia responses. Compared with other bio-molecules, lncRNAs are ideal biomarkers that provide specificity, stability, sensitivity and easy accessibility [<xref ref-type="bibr" rid="CR38">38</xref>]. Most notably, cell-free lncRNAs or those packed in extracellular vesicles can be detectable in various body fluids [<xref ref-type="bibr" rid="CR182">182</xref>]. Hence, the genome-wide annotation of tissue-specific HAL signatures could guide development of promising, non-invasive biomarkers for early diagnosis, prognosis and prediction. Although most lncRNA-targeted treatments are still in their infancy stages, the recent success in RNA-based therapeutics holds promises for future technical innovations. With in-depth characterization of the interplay among hypoxia microenvironment and lncRNA function, more HALs could surely accelerate the design of therapeutics for tumor patients, enabling the targeting of the previously undruggable transcriptome in the near future.</p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec14"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12929_2020_654_MOESM1_ESM.docx"><caption><p><bold>Additional file 1: Table S1. </bold>Hypoxia-associated lncRNAs.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ASO</term><def><p id="Par2">Antisense oligonucleotide</p></def></def-item><def-item><term>bHLH-PAS</term><def><p id="Par3">Basic helix-loop-helix DNA binding proteins of the PER-ARNT-SIM family</p></def></def-item><def-item><term>BRK</term><def><p id="Par4">Breast tumor kinase</p></def></def-item><def-item><term>ceRNA</term><def><p id="Par5">competitive endogenous RNA</p></def></def-item><def-item><term>CRC</term><def><p id="Par6">Colorectal cancer</p></def></def-item><def-item><term>CSC</term><def><p id="Par7">Cancer stem cell</p></def></def-item><def-item><term>DHX9</term><def><p id="Par8">ATP-dependent RNA helicase A</p></def></def-item><def-item><term>EGFR</term><def><p id="Par9">epidermal growth factor receptor</p></def></def-item><def-item><term>EMT</term><def><p id="Par10">Epithelial-mesenchymal transition</p></def></def-item><def-item><term>FDA</term><def><p id="Par11">Food and Drug Administration</p></def></def-item><def-item><term>GC</term><def><p id="Par12">Gastric cancer</p></def></def-item><def-item><term>G-MDSCs</term><def><p id="Par13">Granulocytic myeloid-derived suppressor cells</p></def></def-item><def-item><term>GPNMB</term><def><p id="Par14">Transmembrane glycoprotein NMB</p></def></def-item><def-item><term>GSC</term><def><p id="Par15">Glioblastoma stem-like cells</p></def></def-item><def-item><term>HB-EGF</term><def><p id="Par16">Heparin-binding EGF</p></def></def-item><def-item><term>HCC</term><def><p id="Par17">Hepatocellular cancer</p></def></def-item><def-item><term>HMGA1</term><def><p id="Par18">High mobility group AT-hook 1</p></def></def-item><def-item><term>HAL</term><def><p id="Par19">Hypoxia-associated lncRNAs</p></def></def-item><def-item><term>HUVECs</term><def><p id="Par20">Human umbilical vein endothelial cells</p></def></def-item><def-item><term>IGF2BP2</term><def><p id="Par21">Insulin-like growth factor 2 mRNA-binding protein 2</p></def></def-item><def-item><term>LC</term><def><p id="Par22">Lung cancer</p></def></def-item><def-item><term>lncRNA</term><def><p id="Par23">long non-coding RNA</p></def></def-item><def-item><term>LRRK2</term><def><p id="Par24">Leucine-rich repeat kinase 2</p></def></def-item><def-item><term>M-GSCs</term><def><p id="Par25">Mesenchymal glioblastoma multiforme stem-like cells</p></def></def-item><def-item><term>ncRNA</term><def><p id="Par26">non-coding RNA</p></def></def-item><def-item><term>N.D.</term><def><p id="Par27">Not determined</p></def></def-item><def-item><term>NF90</term><def><p id="Par28">Nuclear factor 90</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par29">Non-small cell lung carcinoma</p></def></def-item><def-item><term>OGT</term><def><p id="Par30">O-linked N-acetylglucosamine transferase</p></def></def-item><def-item><term>OS-9</term><def><p id="Par31">Osteosarcoma amplified-9</p></def></def-item><def-item><term>OSCC</term><def><p id="Par32">Oral squamous cell carcinoma</p></def></def-item><def-item><term>PDAC</term><def><p id="Par33">Pancreatic ductal adenocarcinoma</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par34">Programmed death-ligand 1</p></def></def-item><def-item><term>pHLIP</term><def><p id="Par35">pH-low insertion peptide</p></def></def-item><def-item><term>PNA</term><def><p id="Par36">Peptide nucleic acids</p></def></def-item><def-item><term>RCC</term><def><p id="Par37">Renal Cell Carcinoma</p></def></def-item><def-item><term>SNCG</term><def><p id="Par38">Synuclein gamma</p></def></def-item><def-item><term>TNBC</term><def><p id="Par39">Triple-negative breast cancer</p></def></def-item><def-item><term>UTR</term><def><p id="Par40">Untranslated region</p></def></def-item><def-item><term>VEGF</term><def><p id="Par41">Vascular endothelial growth factor</p></def></def-item><def-item><term>VHL</term><def><p id="Par42">Von Hippel-Lindau protein</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s12929-020-00654-x.</p></sec><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>TCK, JWS and HJK wrote the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was financially supported by the &#x0201c;TMU Research Center of Cancer Translational Medicine&#x0201d; from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (to JWS and HJK). It is also supported by grants MOST108-2321-B-010-013-MY2, MOST108-2320-B-038-011 and MOST107-2320-B-038-055-MY3 from Ministry of Science and Technology of Taiwan (to HJK); TMU106-AE1-B52 from Taipei Medical University and MOST108-2320-B-038-009-MY2 from Ministry of Science and Technology of Taiwan (to JWS). TCK was supported by an independent research scholar grant from Ministry of Science and Technology of Taiwan (MOST 105-2321-B-400-011-MY3), and is indebted to Ting-Feng Tsai (National Yang-Ming University) for her support after the end of the grant.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not Applicable.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par76">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par77">Not Applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par78">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology</article-title><source>Annu Rev Pathol</source><year>2014</year><volume>9</volume><fpage>47</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-012513-104720</pub-id><pub-id pub-id-type="pmid">23937437</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Hypoxia induces genomic DNA demethylation through the activation of HIF-1alpha and transcriptional upregulation of MAT2A in hepatoma cells</article-title><source>Mol Cancer Ther</source><year>2011</year><volume>10</volume><fpage>1113</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-1010</pub-id><pub-id pub-id-type="pmid">21460102</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>AL</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>WY</given-names></name></person-group><article-title>HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer</article-title><source>Expert Opin Ther Targets</source><year>2010</year><volume>14</volume><fpage>1047</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1517/14728222.2010.511617</pub-id><pub-id pub-id-type="pmid">20854179</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>LR</given-names></name><name><surname>Micha</surname><given-names>D</given-names></name><name><surname>Brandenburg</surname><given-names>M</given-names></name><name><surname>Simpson</surname><given-names>KL</given-names></name><name><surname>Morrow</surname><given-names>CJ</given-names></name><name><surname>Denneny</surname><given-names>O</given-names></name><name><surname>Hodgkinson</surname><given-names>C</given-names></name><name><surname>Yunus</surname><given-names>Z</given-names></name><name><surname>Dempsey</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name><name><surname>Makin</surname><given-names>G</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name></person-group><article-title>Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><fpage>1075</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1172/JCI43505</pub-id><pub-id pub-id-type="pmid">21393866</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>NV</given-names></name><name><surname>Kotch</surname><given-names>LE</given-names></name><name><surname>Agani</surname><given-names>F</given-names></name><name><surname>Leung</surname><given-names>SW</given-names></name><name><surname>Laughner</surname><given-names>E</given-names></name><name><surname>Wenger</surname><given-names>RH</given-names></name><name><surname>Gassmann</surname><given-names>M</given-names></name><name><surname>Gearhart</surname><given-names>JD</given-names></name><name><surname>Lawler</surname><given-names>AM</given-names></name><name><surname>Yu</surname><given-names>AY</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha</article-title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1101/gad.12.2.149</pub-id><pub-id pub-id-type="pmid">9436976</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GL</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Rue</surname><given-names>EA</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>92</volume><fpage>5510</fpage><lpage>5514</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.12.5510</pub-id><pub-id pub-id-type="pmid">7539918</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>Y</given-names></name><name><surname>Kanopka</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>WJ</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Poellinger</surname><given-names>L</given-names></name></person-group><article-title>Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>32405</fpage><lpage>32408</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200328200</pub-id><pub-id pub-id-type="pmid">12119283</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>MA</given-names></name><name><surname>Evans</surname><given-names>AJ</given-names></name><name><surname>Hosomi</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Jewett</surname><given-names>MA</given-names></name><name><surname>Ohh</surname><given-names>M</given-names></name></person-group><article-title>Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>1396</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1096/fj.05-3788com</pub-id><pub-id pub-id-type="pmid">16126907</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.441</pub-id><pub-id pub-id-type="pmid">19946328</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaelin</surname><given-names>WG</given-names><suffix>Jr</suffix></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name></person-group><article-title>Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway</article-title><source>Mol Cell</source><year>2008</year><volume>30</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.04.009</pub-id><pub-id pub-id-type="pmid">18498744</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>B</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name></person-group><article-title>Hypoxia-inducible factors, stem cells, and cancer</article-title><source>Cell</source><year>2007</year><volume>129</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.04.019</pub-id><pub-id pub-id-type="pmid">17482542</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhry</surname><given-names>H</given-names></name><name><surname>Schodel</surname><given-names>J</given-names></name><name><surname>Oikonomopoulos</surname><given-names>S</given-names></name><name><surname>Camps</surname><given-names>C</given-names></name><name><surname>Grampp</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Ragoussis</surname><given-names>J</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name></person-group><article-title>Extensive regulation of the non-coding transcriptome by hypoxia: role of HIF in releasing paused RNApol2</article-title><source>EMBO Rep</source><year>2014</year><volume>15</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1002/embr.201337642</pub-id><pub-id pub-id-type="pmid">24363272</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gee</surname><given-names>HE</given-names></name><name><surname>Ivan</surname><given-names>C</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Ivan</surname><given-names>M</given-names></name></person-group><article-title>HypoxamiRs and cancer: from biology to targeted therapy</article-title><source>Antioxid Redox Signal</source><year>2014</year><volume>21</volume><fpage>1220</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1089/ars.2013.5639</pub-id><pub-id pub-id-type="pmid">24111776</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YN</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>ZM</given-names></name><name><surname>Qi</surname><given-names>HX</given-names></name><name><surname>Shi</surname><given-names>ZM</given-names></name><name><surname>Han</surname><given-names>XH</given-names></name><name><surname>Han</surname><given-names>YW</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name></person-group><article-title>Hypoxia-regulated lncRNAs in cancer</article-title><source>Gene</source><year>2016</year><volume>575</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2015.08.049</pub-id><pub-id pub-id-type="pmid">26341058</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhry</surname><given-names>H</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>McIntyre</surname><given-names>A</given-names></name></person-group><article-title>The tumour hypoxia induced non-coding transcriptome</article-title><source>Mol Aspects Med</source><year>2016</year><volume>47-48</volume><fpage>35</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2016.01.003</pub-id><pub-id pub-id-type="pmid">26806607</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>B</given-names></name></person-group><article-title>Influence of the interaction between long noncoding RNAs and hypoxia on tumorigenesis</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>1379</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4457-0</pub-id><pub-id pub-id-type="pmid">26608368</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Genome regulation by long noncoding RNAs</article-title><source>Annu Rev Biochem</source><year>2012</year><volume>81</volume><fpage>145</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-051410-092902</pub-id><pub-id pub-id-type="pmid">22663078</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kung</surname><given-names>JT</given-names></name><name><surname>Colognori</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JT</given-names></name></person-group><article-title>Long noncoding RNAs: past, present, and future</article-title><source>Genetics</source><year>2013</year><volume>193</volume><fpage>651</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1534/genetics.112.146704</pub-id><pub-id pub-id-type="pmid">23463798</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>M</given-names></name></person-group><article-title>Long noncoding RNAs: the search for function</article-title><source>Nat Methods</source><year>2011</year><volume>8</volume><fpage>379</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1038/nmeth0511-379</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>VA</given-names></name><name><surname>Perera</surname><given-names>RJ</given-names></name><name><surname>Khalil</surname><given-names>AM</given-names></name></person-group><article-title>Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><fpage>6391</fpage><lpage>6400</lpage><pub-id pub-id-type="doi">10.1093/nar/gks296</pub-id><pub-id pub-id-type="pmid">22492512</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilusz</surname><given-names>JE</given-names></name><name><surname>Sunwoo</surname><given-names>H</given-names></name><name><surname>Spector</surname><given-names>DL</given-names></name></person-group><article-title>Long noncoding RNAs: functional surprises from the RNA world</article-title><source>Genes Dev</source><year>2009</year><volume>23</volume><fpage>1494</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1101/gad.1800909</pub-id><pub-id pub-id-type="pmid">19571179</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JT</given-names></name></person-group><article-title>Epigenetic regulation by long noncoding RNAs</article-title><source>Science</source><year>2012</year><volume>338</volume><fpage>1435</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1126/science.1231776</pub-id><pub-id pub-id-type="pmid">23239728</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Froberg</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>JT</given-names></name></person-group><article-title>Long noncoding RNAs: fresh perspectives into the RNA world</article-title><source>Trends Biochem Sci</source><year>2014</year><volume>39</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2013.10.002</pub-id><pub-id pub-id-type="pmid">24290031</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Molecular mechanisms of long noncoding RNAs</article-title><source>Mol Cell</source><year>2011</year><volume>43</volume><fpage>904</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.018</pub-id><pub-id pub-id-type="pmid">21925379</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohmdorfer</surname><given-names>G</given-names></name><name><surname>Wierzbicki</surname><given-names>AT</given-names></name></person-group><article-title>Control of chromatin structure by long noncoding RNA</article-title><source>Trends Cell Biol</source><year>2015</year><volume>25</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.07.002</pub-id><pub-id pub-id-type="pmid">26410408</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonasio</surname><given-names>R</given-names></name><name><surname>Shiekhattar</surname><given-names>R</given-names></name></person-group><article-title>Regulation of transcription by long noncoding RNAs</article-title><source>Annu Rev Genet</source><year>2014</year><volume>48</volume><fpage>433</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-120213-092323</pub-id><pub-id pub-id-type="pmid">25251851</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>AM</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Long noncoding RNAs in Cancer pathways</article-title><source>Cancer Cell</source><year>2016</year><volume>29</volume><fpage>452</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.03.010</pub-id><pub-id pub-id-type="pmid">27070700</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Coller</surname><given-names>J</given-names></name></person-group><article-title>RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts</article-title><source>Nat Rev Mol Cell Biol.</source><year>2013</year><volume>14</volume><fpage>699</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/nrm3679</pub-id><pub-id pub-id-type="pmid">24105322</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista</surname><given-names>PJ</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Long noncoding RNAs: cellular address codes in development and disease</article-title><source>Cell</source><year>2013</year><volume>152</volume><fpage>1298</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.02.012</pub-id><pub-id pub-id-type="pmid">23498938</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>C</given-names></name><name><surname>Maquat</surname><given-names>LE</given-names></name></person-group><article-title>lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3&#x02032; UTRs via Alu elements</article-title><source>Nature</source><year>2011</year><volume>470</volume><fpage>284</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/nature09701</pub-id><pub-id pub-id-type="pmid">21307942</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemson</surname><given-names>CM</given-names></name><name><surname>Hutchinson</surname><given-names>JN</given-names></name><name><surname>Sara</surname><given-names>SA</given-names></name><name><surname>Ensminger</surname><given-names>AW</given-names></name><name><surname>Fox</surname><given-names>AH</given-names></name><name><surname>Chess</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>JB</given-names></name></person-group><article-title>An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles</article-title><source>Mol Cell</source><year>2009</year><volume>33</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.01.026</pub-id><pub-id pub-id-type="pmid">19217333</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevtsov</surname><given-names>SP</given-names></name><name><surname>Dundr</surname><given-names>M</given-names></name></person-group><article-title>Nucleation of nuclear bodies by RNA</article-title><source>Nat Cell Biol</source><year>2011</year><volume>13</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/ncb2157</pub-id><pub-id pub-id-type="pmid">21240286</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Long noncoding RNA in genome regulation: prospects and mechanisms</article-title><source>RNA Biol</source><year>2010</year><volume>7</volume><fpage>582</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.4161/rna.7.5.13216</pub-id><pub-id pub-id-type="pmid">20930520</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wapinski</surname><given-names>O</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Long noncoding RNAs and human disease</article-title><source>Trends Cell Biol</source><year>2011</year><volume>21</volume><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2011.04.001</pub-id><pub-id pub-id-type="pmid">21550244</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>EA</given-names></name><name><surname>Brown</surname><given-names>CJ</given-names></name><name><surname>Lam</surname><given-names>WL</given-names></name></person-group><article-title>The functional role of long non-coding RNA in human carcinomas</article-title><source>Mol Cancer</source><year>2011</year><volume>10</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-10-38</pub-id><pub-id pub-id-type="pmid">21489289</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutschner</surname><given-names>T</given-names></name><name><surname>Diederichs</surname><given-names>S</given-names></name></person-group><article-title>The hallmarks of cancer: a long non-coding RNA point of view</article-title><source>RNA Biol</source><year>2012</year><volume>9</volume><fpage>703</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.4161/rna.20481</pub-id><pub-id pub-id-type="pmid">22664915</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spizzo</surname><given-names>R</given-names></name><name><surname>Almeida</surname><given-names>MI</given-names></name><name><surname>Colombatti</surname><given-names>A</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>Long non-coding RNAs and cancer: a new frontier of translational research?</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>4577</fpage><lpage>4587</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.621</pub-id><pub-id pub-id-type="pmid">22266873</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huarte</surname><given-names>M</given-names></name></person-group><article-title>The emerging role of lncRNAs in cancer</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>1253</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1038/nm.3981</pub-id><pub-id pub-id-type="pmid">26540387</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>MT</given-names></name><name><surname>Hu</surname><given-names>JW</given-names></name><name><surname>Yin</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Long noncoding RNA: an emerging paradigm of cancer research</article-title><source>Tumour Biol</source><year>2013</year><volume>34</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s13277-013-0658-6</pub-id><pub-id pub-id-type="pmid">23359273</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhry</surname><given-names>H</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title>Advances in hypoxia-inducible factor biology</article-title><source>Cell Metab</source><year>2018</year><volume>27</volume><fpage>281</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.10.005</pub-id><pub-id pub-id-type="pmid">29129785</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>JW</given-names></name><name><surname>Kung</surname><given-names>HJ</given-names></name></person-group><article-title>Long non-coding RNA and tumor hypoxia: new players ushered toward an old arena</article-title><source>J Biomed Sci</source><year>2017</year><volume>24</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s12929-017-0358-4</pub-id><pub-id pub-id-type="pmid">28789687</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrash-Bingham</surname><given-names>CA</given-names></name><name><surname>Tartof</surname><given-names>KD</given-names></name></person-group><article-title>aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1093/jnci/91.2.143</pub-id><pub-id pub-id-type="pmid">9923855</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>F</given-names></name><name><surname>Vache</surname><given-names>C</given-names></name><name><surname>Clottes</surname><given-names>E</given-names></name></person-group><article-title>Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues</article-title><source>Gene</source><year>2002</year><volume>299</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(02)01049-1</pub-id><pub-id pub-id-type="pmid">12459261</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>A</given-names></name></person-group><article-title>lncRNAs HIF1A-AS2 facilitates the up-regulation of HIF-1alpha by sponging to miR-153-3p, whereby promoting angiogenesis in HUVECs in hypoxia</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>96</volume><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.113</pub-id><pub-id pub-id-type="pmid">28985553</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>C</given-names></name></person-group><article-title>The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1002/jcb.27327</pub-id><pub-id pub-id-type="pmid">30216500</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mineo</surname><given-names>M</given-names></name><name><surname>Ricklefs</surname><given-names>F</given-names></name><name><surname>Rooj</surname><given-names>AK</given-names></name><name><surname>Lyons</surname><given-names>SM</given-names></name><name><surname>Ivanov</surname><given-names>P</given-names></name><name><surname>Ansari</surname><given-names>KI</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name><name><surname>Chiocca</surname><given-names>EA</given-names></name><name><surname>Godlewski</surname><given-names>J</given-names></name><name><surname>Bronisz</surname><given-names>A</given-names></name></person-group><article-title>The long non-coding RNA HIF1A-AS2 facilitates the maintenance of mesenchymal glioblastoma stem-like cells in hypoxic niches</article-title><source>Cell Rep</source><year>2016</year><volume>15</volume><fpage>2500</fpage><lpage>2509</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.018</pub-id><pub-id pub-id-type="pmid">27264189</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Rossignol</surname><given-names>F</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Mounier</surname><given-names>R</given-names></name><name><surname>Couette</surname><given-names>S</given-names></name><name><surname>Clottes</surname><given-names>E</given-names></name><name><surname>Clerici</surname><given-names>C</given-names></name></person-group><article-title>Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>14871</fpage><lpage>14878</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400461200</pub-id><pub-id pub-id-type="pmid">14744852</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>XJ</given-names></name><name><surname>Zheng</surname><given-names>TT</given-names></name><name><surname>Tang</surname><given-names>XY</given-names></name><name><surname>Hua</surname><given-names>KQ</given-names></name></person-group><article-title>Natural antisense transcript of hypoxia-inducible factor 1 regulates hypoxic cell apoptosis in epithelial ovarian cancer</article-title><source>Onco Targets Ther</source><year>2018</year><volume>11</volume><fpage>9101</fpage><lpage>9110</lpage><pub-id pub-id-type="doi">10.2147/OTT.S173816</pub-id><pub-id pub-id-type="pmid">30588022</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Niu</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Long non-coding RNA AGAP2-AS1, functioning AS a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma</article-title><source>J Exp Clin Cancer Res</source><year>2019</year><volume>38</volume><fpage>194</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1188-x</pub-id><pub-id pub-id-type="pmid">31088485</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name></person-group><article-title>Long noncoding RNA ANRIL is activated by hypoxia-inducible factor-1alpha and promotes osteosarcoma cell invasion and suppresses cell apoptosis upon hypoxia</article-title><source>Cancer Cell Int</source><year>2016</year><volume>16</volume><fpage>73</fpage><pub-id pub-id-type="doi">10.1186/s12935-016-0349-7</pub-id><pub-id pub-id-type="pmid">27688736</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Long noncoding RNA BC005927 upregulates EPHB4 and promotes gastric cancer metastasis under hypoxia</article-title><source>Cancer Sci</source><year>2018</year><volume>109</volume><fpage>988</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1111/cas.13519</pub-id><pub-id pub-id-type="pmid">29383777</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>SC</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>ML</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Zhong</surname><given-names>JX</given-names></name><name><surname>Xu</surname><given-names>FY</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name></person-group><article-title>Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>5811</fpage><lpage>5828</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0382-1</pub-id><pub-id pub-id-type="pmid">29970904</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name></person-group><article-title>The long noncoding RNA Cancer susceptibility candidate 9 promotes nasopharyngeal carcinogenesis via stabilizing HIF1alpha</article-title><source>DNA Cell Biol</source><year>2017</year><volume>36</volume><fpage>394</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1089/dna.2016.3615</pub-id><pub-id pub-id-type="pmid">28398871</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name></person-group><article-title>Hypoxia-induced feedback of HIF-1alpha and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>4795</fpage><lpage>4810</lpage><pub-id pub-id-type="doi">10.7150/thno.30988</pub-id><pub-id pub-id-type="pmid">31367258</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name></person-group><article-title>LncRNA CPS1-IT1 suppresses EMT and metastasis of colorectal cancer by inhibiting hypoxia-induced autophagy through inactivation of HIF-1alpha</article-title><source>Biochimie</source><year>2018</year><volume>144</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2017.10.002</pub-id><pub-id pub-id-type="pmid">29017924</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chai</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><article-title>Hypoxia-regulated lncRNA CRPAT4 promotes cell migration via regulating AVL9 in clear cell renal cell carcinomas</article-title><source>Onco Targets Ther</source><year>2018</year><volume>11</volume><fpage>4537</fpage><lpage>4545</lpage><pub-id pub-id-type="doi">10.2147/OTT.S169155</pub-id><pub-id pub-id-type="pmid">30122945</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>YP</given-names></name><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>YQ</given-names></name><name><surname>Zhang</surname><given-names>PP</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>XH</given-names></name><name><surname>He</surname><given-names>QM</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>YQ</given-names></name></person-group><article-title>Long non-coding RNA DANCR stabilizes HIF-1alpha and promotes metastasis by interacting with NF90/NF45 complex in nasopharyngeal carcinoma</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>5676</fpage><lpage>5689</lpage><pub-id pub-id-type="doi">10.7150/thno.28538</pub-id><pub-id pub-id-type="pmid">30555573</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, Xu W, Wu C, Li J, Zhan F, Wu Y, Yan H. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica. 2019;104:218289.</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Mo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name></person-group><article-title>Hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122-5p/CTNND2 axis</article-title><source>Biochem Biophys Res Commun</source><year>2019</year><volume>518</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.08.039</pub-id><pub-id pub-id-type="pmid">31421822</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YW</given-names></name><name><surname>Chen</surname><given-names>YF</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Huo</surname><given-names>YM</given-names></name><name><surname>Liu</surname><given-names>DJ</given-names></name><name><surname>Hua</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>JF</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Fu</surname><given-names>XL</given-names></name><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name></person-group><article-title>A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma</article-title><source>Br J Cancer</source><year>2014</year><volume>111</volume><fpage>2131</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.520</pub-id><pub-id pub-id-type="pmid">25314054</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Bei</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name></person-group><article-title>Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients</article-title><source>Prostate</source><year>2017</year><volume>77</volume><fpage>1107</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1002/pros.23367</pub-id><pub-id pub-id-type="pmid">28585762</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>AM</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>ZW</given-names></name><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>SZ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2019</year><volume>23</volume><fpage>5802</fpage><lpage>5814</lpage><pub-id pub-id-type="pmid">31298332</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Ou ZL, Zhang M, Ji LD, Luo Z, Han T, Lu YB, Li YX. Long noncoding RNA FEZF1-AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR-142/HIF-1alpha and miR-133a/EGFR upon hypoxia/normoxia. J Cell Physiol. 2019;234:15407&#x02013;19.</mixed-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group><article-title>Hypoxia promotes gastric Cancer malignancy partly through the HIF-1alpha dependent transcriptional activation of the long non-coding RNA GAPLINC</article-title><source>Front Physiol</source><year>2016</year><volume>7</volume><fpage>420</fpage><pub-id pub-id-type="pmid">27729869</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name></person-group><article-title>Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>6890</fpage><lpage>6902</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0686</pub-id><pub-id pub-id-type="pmid">25277524</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Fan</surname><given-names>WJ</given-names></name><name><surname>Meng</surname><given-names>YT</given-names></name><name><surname>Li</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>TT</given-names></name><name><surname>Cui</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>HF</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>XF</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>DK</given-names></name><name><surname>Xu</surname><given-names>LZ</given-names></name><name><surname>Xie</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>WX</given-names></name><name><surname>Lam</surname><given-names>EW</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>1062</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.368</pub-id><pub-id pub-id-type="pmid">29106390</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Corrado C, Costa V, Giavaresi G, Calabrese A, Conigliaro A, Alessandro R. Long non coding RNA H19: a new player in hypoxia-induced multiple myeloma cell dissemination. Int J Mol Sci. 2019;20:801.</mixed-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Nie</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhi</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>You</surname><given-names>Y</given-names></name></person-group><article-title>Hypoxia induces H19 expression through direct and indirect Hif-1alpha activity, promoting oncogenic effects in glioblastoma</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>45029</fpage><pub-id pub-id-type="doi">10.1038/srep45029</pub-id><pub-id pub-id-type="pmid">28327666</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matouk</surname><given-names>IJ</given-names></name><name><surname>DeGroot</surname><given-names>N</given-names></name><name><surname>Mezan</surname><given-names>S</given-names></name><name><surname>Ayesh</surname><given-names>S</given-names></name><name><surname>Abu-lail</surname><given-names>R</given-names></name><name><surname>Hochberg</surname><given-names>A</given-names></name><name><surname>Galun</surname><given-names>E</given-names></name></person-group><article-title>The H19 non-coding RNA is essential for human tumor growth</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e845</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0000845</pub-id><pub-id pub-id-type="pmid">17786216</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matouk</surname><given-names>IJ</given-names></name><name><surname>Mezan</surname><given-names>S</given-names></name><name><surname>Mizrahi</surname><given-names>A</given-names></name><name><surname>Ohana</surname><given-names>P</given-names></name><name><surname>Abu-Lail</surname><given-names>R</given-names></name><name><surname>Fellig</surname><given-names>Y</given-names></name><name><surname>Degroot</surname><given-names>N</given-names></name><name><surname>Galun</surname><given-names>E</given-names></name><name><surname>Hochberg</surname><given-names>A</given-names></name></person-group><article-title>The oncofetal H19 RNA connection: hypoxia, p53 and cancer</article-title><source>Biochim Biophys Acta</source><year>2010</year><volume>1803</volume><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2010.01.010</pub-id><pub-id pub-id-type="pmid">20117150</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voellenkle</surname><given-names>C</given-names></name><name><surname>Garcia-Manteiga</surname><given-names>JM</given-names></name><name><surname>Pedrotti</surname><given-names>S</given-names></name><name><surname>Perfetti</surname><given-names>A</given-names></name><name><surname>De Toma</surname><given-names>I</given-names></name><name><surname>Da Silva</surname><given-names>D</given-names></name><name><surname>Maimone</surname><given-names>B</given-names></name><name><surname>Greco</surname><given-names>S</given-names></name><name><surname>Fasanaro</surname><given-names>P</given-names></name><name><surname>Creo</surname><given-names>P</given-names></name><name><surname>Zaccagnini</surname><given-names>G</given-names></name><name><surname>Gaetano</surname><given-names>C</given-names></name><name><surname>Martelli</surname><given-names>F</given-names></name></person-group><article-title>Implication of long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>24141</fpage><pub-id pub-id-type="doi">10.1038/srep24141</pub-id><pub-id pub-id-type="pmid">27063004</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><mixed-citation publication-type="other">Bacci L, Aiello A, Ripoli C, Loria R, Pugliese D, Pierconti F, Rotili D, Strigari L, Pinto F, Bassi PF, Mai A, Grassi C, Pontecorvi A, Falcioni R, Farsetti A, Nanni S. H19-dependent transcriptional regulation of beta3 and beta4 Integrins upon estrogen and hypoxia favors metastatic potential in prostate Cancer. Int J Mol Sci. 2019;20:4012.</mixed-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matouk</surname><given-names>IJ</given-names></name><name><surname>Raveh</surname><given-names>E</given-names></name><name><surname>Abu-lail</surname><given-names>R</given-names></name><name><surname>Mezan</surname><given-names>S</given-names></name><name><surname>Gilon</surname><given-names>M</given-names></name><name><surname>Gershtain</surname><given-names>E</given-names></name><name><surname>Birman</surname><given-names>T</given-names></name><name><surname>Gallula</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Barkali</surname><given-names>M</given-names></name><name><surname>Richler</surname><given-names>C</given-names></name><name><surname>Fellig</surname><given-names>Y</given-names></name><name><surname>Sorin</surname><given-names>V</given-names></name><name><surname>Hubert</surname><given-names>A</given-names></name><name><surname>Hochberg</surname><given-names>A</given-names></name><name><surname>Czerniak</surname><given-names>A</given-names></name></person-group><article-title>Oncofetal H19 RNA promotes tumor metastasis</article-title><source>Biochim Biophys Acta</source><year>2014</year><volume>1843</volume><fpage>1414</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.03.023</pub-id><pub-id pub-id-type="pmid">24703882</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>ZH</given-names></name><name><surname>Wu</surname><given-names>DM</given-names></name><name><surname>Fan</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>ZF</given-names></name><name><surname>Chen</surname><given-names>GQ</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group><article-title>Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><fpage>18724</fpage><lpage>18735</lpage><pub-id pub-id-type="doi">10.1002/jcb.29182</pub-id><pub-id pub-id-type="pmid">31219199</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma</article-title><source>Mol Carcinog</source><year>2017</year><volume>56</volume><fpage>2210</fpage><lpage>2222</lpage><pub-id pub-id-type="doi">10.1002/mc.22674</pub-id><pub-id pub-id-type="pmid">28485478</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name></person-group><article-title>A novel long non-coding RNA, hypoxia-inducible factor-2alpha promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro</article-title><source>Mol Med Rep</source><year>2015</year><volume>11</volume><fpage>2534</fpage><lpage>2540</lpage><pub-id pub-id-type="doi">10.3892/mmr.2014.3024</pub-id><pub-id pub-id-type="pmid">25434862</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>D</given-names></name></person-group><article-title>LncRNA HIF2PUT inhibited osteosarcoma stem cells proliferation, migration and invasion by regulating HIF2 expression</article-title><source>Artif Cells Nanomed Biotechnol</source><year>2019</year><volume>47</volume><fpage>1342</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1080/21691401.2019.1596934</pub-id><pub-id pub-id-type="pmid">30966832</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferdin</surname><given-names>J</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Nicoloso</surname><given-names>MS</given-names></name><name><surname>Shah</surname><given-names>MY</given-names></name><name><surname>Devlin</surname><given-names>C</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Cortez</surname><given-names>MA</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Czerniak</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name><name><surname>Voorhoeve</surname><given-names>MP</given-names></name><name><surname>Reginato</surname><given-names>MJ</given-names></name><name><surname>Negrini</surname><given-names>M</given-names></name><name><surname>Davuluri</surname><given-names>RV</given-names></name><name><surname>Kunej</surname><given-names>T</given-names></name><name><surname>Ivan</surname><given-names>M</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts</article-title><source>Cell Death Differ</source><year>2013</year><volume>20</volume><fpage>1675</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1038/cdd.2013.119</pub-id><pub-id pub-id-type="pmid">24037088</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>O</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>WZ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Cai</surname><given-names>GY</given-names></name><name><surname>He</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>XM</given-names></name></person-group><article-title>LncRNA HOTAIR regulates HIF-1alpha/AXL signaling through inhibition of miR-217 in renal cell carcinoma</article-title><source>Cell Death Dis</source><year>2017</year><volume>8</volume><fpage>e2772</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.181</pub-id><pub-id pub-id-type="pmid">28492542</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Chi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Long noncoding RNA HOTAIR, a hypoxia-inducible factor-1alpha activated driver of malignancy, enhances hypoxic cancer cell proliferation, migration, and invasion in non-small cell lung cancer</article-title><source>Tumour Biol</source><year>2015</year><volume>36</volume><fpage>9179</fpage><lpage>9188</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3453-8</pub-id><pub-id pub-id-type="pmid">26088446</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Liu</surname><given-names>ZL</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>ZX</given-names></name><name><surname>De</surname><given-names>W</given-names></name></person-group><article-title>The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>464</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-13-464</pub-id><pub-id pub-id-type="pmid">24103700</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name></person-group><article-title>Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>95</volume><fpage>711</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.08.133</pub-id><pub-id pub-id-type="pmid">28886531</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Thorne</surname><given-names>RF</given-names></name><name><surname>Zhang</surname><given-names>XD</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name></person-group><article-title>LncRNA IDH1-AS1 links the functions of c-Myc and HIF1alpha via IDH1 to regulate the Warburg effect</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>E1465</fpage><lpage>E1E74</lpage><pub-id pub-id-type="doi">10.1073/pnas.1711257115</pub-id><pub-id pub-id-type="pmid">29378948</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Hypoxia-sensitive LINC01436 is regulated by E2F6 and acts as an oncogene by targeting miR-30a-3p in non-small cell lung cancer</article-title><source>Mol Oncol</source><year>2019</year><volume>13</volume><fpage>840</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12437</pub-id><pub-id pub-id-type="pmid">30614188</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name></person-group><article-title>Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect</article-title><source>Mol Cell</source><year>2014</year><volume>53</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.11.004</pub-id><pub-id pub-id-type="pmid">24316222</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name></person-group><article-title>LincRNA-p21 knockdown enhances radiosensitivity of hypoxic tumor cells by reducing autophagy through HIF-1/Akt/mTOR/P70S6K pathway</article-title><source>Exp Cell Res</source><year>2017</year><volume>358</volume><fpage>188</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2017.06.016</pub-id><pub-id pub-id-type="pmid">28689810</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>IK</given-names></name><name><surname>Haga</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>T</given-names></name></person-group><article-title>Modulation of hypoxia-signaling pathways by extracellular linc-RoR</article-title><source>J Cell Sci</source><year>2014</year><volume>127</volume><fpage>1585</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.1242/jcs.141069</pub-id><pub-id pub-id-type="pmid">24463816</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Hawke</surname><given-names>DH</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>PK</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer</article-title><source>Nat Cell Biol</source><year>2016</year><volume>18</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/ncb3295</pub-id><pub-id pub-id-type="pmid">26751287</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>JW</given-names></name><name><surname>Chiang</surname><given-names>WF</given-names></name><name><surname>Wu</surname><given-names>ATH</given-names></name><name><surname>Wu</surname><given-names>MH</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Yu</surname><given-names>YL</given-names></name><name><surname>Hung</surname><given-names>YW</given-names></name><name><surname>Wang</surname><given-names>WC</given-names></name><name><surname>Chu</surname><given-names>CY</given-names></name><name><surname>Hung</surname><given-names>CL</given-names></name><name><surname>Changou</surname><given-names>CA</given-names></name><name><surname>Yen</surname><given-names>Y</given-names></name><name><surname>Kung</surname><given-names>HJ</given-names></name></person-group><article-title>Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1alpha co-activator driving oral cancer progression</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>15874</fpage><pub-id pub-id-type="doi">10.1038/ncomms15874</pub-id><pub-id pub-id-type="pmid">28639619</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Hypoxia-inducible lncRNA-AK058003 promotes gastric cancer metastasis by targeting gamma-synuclein</article-title><source>Neoplasia</source><year>2014</year><volume>16</volume><fpage>1094</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2014.10.008</pub-id><pub-id pub-id-type="pmid">25499222</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Maldonado</surname><given-names>L</given-names></name><name><surname>Tiana</surname><given-names>M</given-names></name><name><surname>Roche</surname><given-names>O</given-names></name><name><surname>Prado-Cabrero</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>L</given-names></name><name><surname>Fernandez-Barral</surname><given-names>A</given-names></name><name><surname>Guijarro-Munoz</surname><given-names>I</given-names></name><name><surname>Favaro</surname><given-names>E</given-names></name><name><surname>Moreno-Bueno</surname><given-names>G</given-names></name><name><surname>Sanz</surname><given-names>L</given-names></name><name><surname>Aragones</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><name><surname>Volpert</surname><given-names>O</given-names></name><name><surname>Jimenez</surname><given-names>B</given-names></name><name><surname>del Peso</surname><given-names>L</given-names></name></person-group><article-title>EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>2609</fpage><lpage>2620</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.200</pub-id><pub-id pub-id-type="pmid">25023702</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Venzor</surname><given-names>A</given-names></name><name><surname>Mandujano-Tinoco</surname><given-names>EA</given-names></name><name><surname>Lizarraga</surname><given-names>F</given-names></name><name><surname>Zampedri</surname><given-names>C</given-names></name><name><surname>Krotzsch</surname><given-names>E</given-names></name><name><surname>Salgado</surname><given-names>RM</given-names></name><name><surname>Davila-Borja</surname><given-names>VM</given-names></name><name><surname>Encarnacion-Guevara</surname><given-names>S</given-names></name><name><surname>Melendez-Zajgla</surname><given-names>J</given-names></name><name><surname>Maldonado</surname><given-names>V</given-names></name></person-group><article-title>Microenvironment-regulated lncRNA-HAL is able to promote stemness in breast cancer cells</article-title><source>Biochim Biophys Acta Mol Cell Res</source><year>2019</year><volume>1866</volume><fpage>118523</fpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2019.118523</pub-id><pub-id pub-id-type="pmid">31401107</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Huo</surname><given-names>XS</given-names></name><name><surname>Yuan</surname><given-names>SX</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>WP</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>SH</given-names></name></person-group><article-title>Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis</article-title><source>Mol Cell</source><year>2013</year><volume>49</volume><fpage>1083</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.01.010</pub-id><pub-id pub-id-type="pmid">23395002</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Gasiewicz</surname><given-names>TA</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name></person-group><article-title>Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2alpha/C-MYC axis under hypoxia</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><fpage>4866</fpage><lpage>4880</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.19</pub-id><pub-id pub-id-type="pmid">26973243</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>lncTCF7 is a negative prognostic factor, and knockdown of lncTCF7 inhibits migration, proliferation and tumorigenicity in glioma</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>17456</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17340-y</pub-id><pub-id pub-id-type="pmid">29234033</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name></person-group><article-title>A MALAT1/HIF-2alpha feedback loop contributes to arsenite carcinogenesis</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>5769</fpage><lpage>5787</lpage><pub-id pub-id-type="pmid">26735578</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ling</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>The lncRNA MALAT1, acting through HIF-1alpha stabilization, enhances arsenite-induced glycolysis in human hepatic L-02 cells</article-title><source>Biochim Biophys Acta</source><year>1862</year><volume>2016</volume><fpage>1685</fpage><lpage>1695</lpage></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name></person-group><article-title>Hypoxia exposure upregulates MALAT-1 and regulates the transcriptional activity of PTB-associated splicing factor in A549 lung adenocarcinoma cells</article-title><source>Oncol Lett</source><year>2018</year><volume>16</volume><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">29928414</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Lian</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Garen</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>X</given-names></name></person-group><article-title>Role of human noncoding RNAs in the control of tumorigenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>12956</fpage><lpage>12961</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906005106</pub-id><pub-id pub-id-type="pmid">19625619</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>ZB</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Bai</surname><given-names>XF</given-names></name></person-group><article-title>Long noncoding RNA MALAT1 regulates hepatocellular carcinoma growth under hypoxia via sponging MicroRNA-200a</article-title><source>Yonsei Med J</source><year>2019</year><volume>60</volume><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.3349/ymj.2019.60.8.727</pub-id><pub-id pub-id-type="pmid">31347327</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>XY</given-names></name><name><surname>Lei</surname><given-names>BX</given-names></name><name><surname>Lin</surname><given-names>YY</given-names></name><name><surname>Sui</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>ML</given-names></name><name><surname>Zhuang</surname><given-names>ZQ</given-names></name><name><surname>Dong</surname><given-names>JT</given-names></name><name><surname>Jin</surname><given-names>DM</given-names></name><name><surname>Yan</surname><given-names>TB</given-names></name></person-group><article-title>Long noncoding RNA MEG3 silencing protects against hypoxia-induced pheochromocytoma-12 cell injury through inhibition of TIMP2 promoter methylation</article-title><source>J Cell Physiol</source><year>2020</year><volume>235</volume><fpage>1649</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1002/jcp.29085</pub-id><pub-id pub-id-type="pmid">31392726</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>FY</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>JX</given-names></name><name><surname>Deng</surname><given-names>SJ</given-names></name><name><surname>Liu</surname><given-names>ML</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name></person-group><article-title>LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1alpha</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>5298</fpage><lpage>5314</lpage><pub-id pub-id-type="doi">10.7150/thno.34559</pub-id><pub-id pub-id-type="pmid">31410216</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name></person-group><article-title>Overexpression of HIF-2alpha-dependent NEAT1 promotes the progression of non-small cell lung Cancer through miR-101-3p/SOX9/Wnt/beta-catenin signal pathway</article-title><source>Cell Physiol Biochem</source><year>2019</year><volume>52</volume><fpage>368</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.33594/000000026</pub-id><pub-id pub-id-type="pmid">30845377</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhry</surname><given-names>H</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name></person-group><article-title>Hypoxic regulation of the noncoding genome and NEAT1</article-title><source>Brief Funct Genomics</source><year>2016</year><volume>15</volume><fpage>174</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1093/bfgp/elv050</pub-id><pub-id pub-id-type="pmid">26590207</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhry</surname><given-names>H</given-names></name><name><surname>Albukhari</surname><given-names>A</given-names></name><name><surname>Morotti</surname><given-names>M</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Moralli</surname><given-names>D</given-names></name><name><surname>Smythies</surname><given-names>J</given-names></name><name><surname>Schodel</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>CM</given-names></name><name><surname>Camps</surname><given-names>C</given-names></name><name><surname>Buffa</surname><given-names>F</given-names></name><name><surname>Ratcliffe</surname><given-names>P</given-names></name><name><surname>Ragoussis</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name></person-group><article-title>Tumor hypoxia induces nuclear paraspeckle formation through HIF-2alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>4482</fpage><lpage>4490</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.378</pub-id><pub-id pub-id-type="pmid">25417700</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelli</surname><given-names>A</given-names></name><name><surname>Nolan</surname><given-names>KA</given-names></name><name><surname>Santambrogio</surname><given-names>S</given-names></name><name><surname>Goncalves</surname><given-names>AF</given-names></name><name><surname>Schonenberger</surname><given-names>MJ</given-names></name><name><surname>Guinot</surname><given-names>A</given-names></name><name><surname>Frew</surname><given-names>IJ</given-names></name><name><surname>Marti</surname><given-names>HH</given-names></name><name><surname>Hoogewijs</surname><given-names>D</given-names></name><name><surname>Wenger</surname><given-names>RH</given-names></name></person-group><article-title>Induction of long noncoding RNA MALAT1 in hypoxic mice</article-title><source>Hypoxia (Auckl)</source><year>2015</year><volume>3</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">27774481</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Yeh</surname><given-names>CC</given-names></name><name><surname>Chao</surname><given-names>LY</given-names></name><name><surname>Tsai</surname><given-names>MH</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Chuang</surname><given-names>EY</given-names></name><name><surname>Lai</surname><given-names>LC</given-names></name></person-group><article-title>The hypoxia-responsive lncRNA NDRG-OT1 promotes NDRG1 degradation via ubiquitin-mediated proteolysis in breast cancer cells</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>10470</fpage><lpage>10482</lpage><pub-id pub-id-type="pmid">29535820</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>C</given-names></name><name><surname>Huo</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name></person-group><article-title>Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer</article-title><source>Mol Cancer</source><year>2017</year><volume>16</volume><fpage>169</fpage><pub-id pub-id-type="doi">10.1186/s12943-017-0738-0</pub-id><pub-id pub-id-type="pmid">29121972</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>SJ</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>SP</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Xiang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>QY</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Niu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name></person-group><article-title>Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>6000</fpage><lpage>6014</lpage><pub-id pub-id-type="pmid">26755660</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>HY</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>ZC</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Meng</surname><given-names>XY</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Hypoxia-induced LncRNA PCGEM1 promotes invasion and metastasis of gastric cancer through regulating SNAI1</article-title><source>Clin Transl Oncol</source><year>2019</year><volume>21</volume><fpage>1142</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1007/s12094-019-02035-9</pub-id><pub-id pub-id-type="pmid">30690667</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Mou</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1alpha</article-title><source>Cell Death Differ</source><year>2020</year><volume>27</volume><fpage>695</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1038/s41418-019-0381-y</pub-id><pub-id pub-id-type="pmid">31320749</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name></person-group><article-title>Long non-coding RNA PVT1/miR-150/ HIG2 Axis regulates the proliferation, invasion and the balance of Iron metabolism of hepatocellular carcinoma</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>49</volume><fpage>1403</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1159/000493445</pub-id><pub-id pub-id-type="pmid">30205391</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name><name><surname>Chen</surname><given-names>JQ</given-names></name><name><surname>Wang</surname><given-names>SH</given-names></name><name><surname>Hao</surname><given-names>LQ</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name></person-group><article-title>The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>88</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.01.049</pub-id><pub-id pub-id-type="pmid">28122299</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><article-title>LncRNA PVT1 regulate expression of HIF1alpha via functioning as ceRNA for miR199a5p in nonsmall cell lung cancer under hypoxia</article-title><source>Mol Med Rep</source><year>2018</year><volume>17</volume><fpage>1105</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">29115513</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iden</surname><given-names>M</given-names></name><name><surname>Fye</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Chowdhury</surname><given-names>T</given-names></name><name><surname>Ramchandran</surname><given-names>R</given-names></name><name><surname>Rader</surname><given-names>JS</given-names></name></person-group><article-title>The lncRNA PVT1 contributes to the cervical Cancer phenotype and associates with poor patient prognosis</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0156274</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0156274</pub-id><pub-id pub-id-type="pmid">27232880</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group><article-title>An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>6163</fpage><lpage>6172</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0010</pub-id><pub-id pub-id-type="pmid">23026137</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name></person-group><article-title>Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1alpha/VEGFA signalling in hepatocellular carcinoma</article-title><source>J Exp Clin Cancer Res</source><year>2018</year><volume>37</volume><fpage>113</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-0727-1</pub-id><pub-id pub-id-type="pmid">29866133</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name></person-group><article-title>Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1alpha feedback regulatory loop</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>14733</fpage><lpage>14743</lpage><pub-id pub-id-type="doi">10.1007/s13277-016-5348-8</pub-id><pub-id pub-id-type="pmid">27629141</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Che</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Long non-coding RNA UCA1 upregulation promotes the migration of hypoxia-resistant gastric cancer cells through the miR-7-5p/EGFR axis</article-title><source>Exp Cell Res</source><year>2018</year><volume>368</volume><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2018.04.030</pub-id><pub-id pub-id-type="pmid">29723509</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway</article-title><source>J Cell Biochem</source><year>2018</year><volume>119</volume><fpage>6296</fpage><lpage>6308</lpage><pub-id pub-id-type="doi">10.1002/jcb.26899</pub-id><pub-id pub-id-type="pmid">29663500</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1alpha-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion</article-title><source>Tumour Biol</source><year>2014</year><volume>35</volume><fpage>6901</fpage><lpage>6912</lpage><pub-id pub-id-type="doi">10.1007/s13277-014-1925-x</pub-id><pub-id pub-id-type="pmid">24737584</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion</article-title><source>FEBS Lett</source><year>2008</year><volume>582</volume><fpage>1919</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2008.05.012</pub-id><pub-id pub-id-type="pmid">18501714</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name></person-group><article-title>HIF1alphainduced upregulation of lncRNA UCA1 promotes cell growth in osteosarcoma by inactivating the PTEN/AKT signaling pathway</article-title><source>Oncol Rep</source><year>2018</year><volume>39</volume><fpage>1072</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">29328452</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarty</surname><given-names>G</given-names></name><name><surname>Loeb</surname><given-names>DM</given-names></name></person-group><article-title>Hypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0119837</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0119837</pub-id><pub-id pub-id-type="pmid">25794157</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallosso</surname><given-names>AR</given-names></name><name><surname>Hancock</surname><given-names>AL</given-names></name><name><surname>Malik</surname><given-names>S</given-names></name><name><surname>Salpekar</surname><given-names>A</given-names></name><name><surname>King-Underwood</surname><given-names>L</given-names></name><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><name><surname>Moorwood</surname><given-names>K</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Malik</surname><given-names>KT</given-names></name><name><surname>Brown</surname><given-names>KW</given-names></name></person-group><article-title>Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer</article-title><source>RNA</source><year>2007</year><volume>13</volume><fpage>2287</fpage><lpage>2299</lpage><pub-id pub-id-type="doi">10.1261/rna.562907</pub-id><pub-id pub-id-type="pmid">17940140</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><article-title>The lncRNA ZEB2-AS1 is upregulated in gastric cancer and affects cell proliferation and invasion via miR-143-5p/HIF-1alpha axis</article-title><source>Onco Targets Ther</source><year>2019</year><volume>12</volume><fpage>657</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.2147/OTT.S175521</pub-id><pub-id pub-id-type="pmid">30705594</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzen</surname><given-names>JM</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name></person-group><article-title>Long noncoding RNAs in kidney and cardiovascular diseases</article-title><source>Nat Rev Nephrol</source><year>2016</year><volume>12</volume><fpage>360</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2016.51</pub-id><pub-id pub-id-type="pmid">27140855</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Azzouzi</surname><given-names>H</given-names></name><name><surname>Doevendans</surname><given-names>PA</given-names></name><name><surname>Sluijter</surname><given-names>JP</given-names></name></person-group><article-title>Long non-coding RNAs in heart failure: an obvious lnc</article-title><source>Ann Transl Med</source><year>2016</year><volume>4</volume><fpage>182</fpage><pub-id pub-id-type="doi">10.21037/atm.2016.05.06</pub-id><pub-id pub-id-type="pmid">27275495</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>JR</given-names></name><name><surname>Lim</surname><given-names>KY</given-names></name><name><surname>Sepramaniam</surname><given-names>S</given-names></name><name><surname>Karolina</surname><given-names>DS</given-names></name><name><surname>Armugam</surname><given-names>A</given-names></name><name><surname>Jeyaseelan</surname><given-names>K</given-names></name></person-group><article-title>Non-coding RNAs as potential Neuroprotectants against ischemic brain injury</article-title><source>Brain Sci</source><year>2013</year><volume>3</volume><fpage>360</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.3390/brainsci3010360</pub-id><pub-id pub-id-type="pmid">24961318</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><mixed-citation publication-type="other">Jin Q, Zhao Z, Zhao Q, Yu X, Yan L, Zhang Y, Luo Q, Liu Z. Long noncoding RNAs: emerging roles in pulmonary hypertension. Heart Fail Rev. 2019. 10.1007/s10741-019-09866-2.</mixed-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>YX</given-names></name><name><surname>Jia</surname><given-names>QJ</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Qi</surname><given-names>ZW</given-names></name><name><surname>Zhang</surname><given-names>JP</given-names></name></person-group><article-title>Long noncoding RNAs in pathological cardiac remodeling: a review of the update literature</article-title><source>Biomed Res Int</source><year>2019</year><volume>2019</volume><fpage>7159592</fpage><pub-id pub-id-type="pmid">31355277</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>G</given-names></name><name><surname>Kolling</surname><given-names>M</given-names></name><name><surname>Lorenzen</surname><given-names>JM</given-names></name></person-group><article-title>The hypoxic kidney: pathogenesis and noncoding RNA-based therapeutic strategies</article-title><source>Swiss Med Wkly</source><year>2019</year><volume>149</volume><fpage>w14703</fpage><pub-id pub-id-type="pmid">30636273</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>XJ</given-names></name><name><surname>Zheng</surname><given-names>TT</given-names></name><name><surname>Tang</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hua</surname><given-names>KQ</given-names></name></person-group><article-title>The Exosomal long noncoding RNA aHIF is upregulated in serum from patients with endometriosis and promotes angiogenesis in endometriosis</article-title><source>Reprod Sci</source><year>2019</year><volume>26</volume><fpage>1590</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1177/1933719119831775</pub-id><pub-id pub-id-type="pmid">30808247</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>HL</given-names></name><name><surname>Hu</surname><given-names>GW</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Kuang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>GH</given-names></name></person-group><article-title>Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2</article-title><source>Oncol Rep</source><year>2017</year><volume>38</volume><fpage>785</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.3892/or.2017.5742</pub-id><pub-id pub-id-type="pmid">28656228</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>P-P</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>E</given-names></name></person-group><article-title>Extracellular vesicle-packaged HIF-1&#x003b1;-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells</article-title><source>Nat Cell Biol</source><year>2019</year><volume>21</volume><fpage>498</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0299-0</pub-id><pub-id pub-id-type="pmid">30936474</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name></person-group><article-title>The expression pattern of long non-coding RNA PVT1 in tumor tissues and in extracellular vesicles of colorectal cancer correlates with cancer progression</article-title><source>Tumour Biol</source><year>2017</year><volume>39</volume><fpage>1010428317699122</fpage><pub-id pub-id-type="pmid">28381186</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Xiang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>An</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1</article-title><source>Mol Cancer</source><year>2017</year><volume>16</volume><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/s12943-017-0714-8</pub-id><pub-id pub-id-type="pmid">28841829</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>JJ</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Unique features of long non-coding RNA biogenesis and function</article-title><source>Nat Rev Genet</source><year>2016</year><volume>17</volume><fpage>47</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nrg.2015.10</pub-id><pub-id pub-id-type="pmid">26666209</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>JH</given-names></name><name><surname>Mahon</surname><given-names>PC</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name><name><surname>Krishnamachary</surname><given-names>B</given-names></name><name><surname>Pearson</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>DA</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha</article-title><source>Mol Cell</source><year>2005</year><volume>17</volume><fpage>503</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.01.011</pub-id><pub-id pub-id-type="pmid">15721254</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>MZ</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Weng</surname><given-names>MZ</given-names></name><name><surname>Zhang</surname><given-names>MD</given-names></name><name><surname>Qin</surname><given-names>YY</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>WJ</given-names></name><name><surname>Quan</surname><given-names>ZW</given-names></name></person-group><article-title>Long non-coding RNA-LET is a positive prognostic factor and exhibits tumor-suppressive activity in gallbladder cancer</article-title><source>Mol Carcinog</source><year>2015</year><volume>54</volume><fpage>1397</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1002/mc.22215</pub-id><pub-id pub-id-type="pmid">25213660</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwano</surname><given-names>Y</given-names></name><name><surname>Pullmann</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Marasa</surname><given-names>BS</given-names></name><name><surname>Abdelmohsen</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>EK</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Martindale</surname><given-names>JL</given-names></name><name><surname>Zhan</surname><given-names>M</given-names></name><name><surname>Gorospe</surname><given-names>M</given-names></name></person-group><article-title>NF90 selectively represses the translation of target mRNAs bearing an AU-rich signature motif</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><fpage>225</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp861</pub-id><pub-id pub-id-type="pmid">19850717</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertozzi</surname><given-names>D</given-names></name><name><surname>Iurlaro</surname><given-names>R</given-names></name><name><surname>Sordet</surname><given-names>O</given-names></name><name><surname>Marinello</surname><given-names>J</given-names></name><name><surname>Zaffaroni</surname><given-names>N</given-names></name><name><surname>Capranico</surname><given-names>G</given-names></name></person-group><article-title>Characterization of novel antisense HIF-1alpha transcripts in human cancers</article-title><source>Cell Cycle</source><year>2011</year><volume>10</volume><fpage>3189</fpage><lpage>3197</lpage><pub-id pub-id-type="doi">10.4161/cc.10.18.17183</pub-id><pub-id pub-id-type="pmid">21897117</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>Huang</surname><given-names>MD</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>TP</given-names></name><name><surname>Zhang</surname><given-names>EB</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>YQ</given-names></name></person-group><article-title>Antisense long noncoding RNA HIF1A-AS2 is upregulated in gastric Cancer and associated with poor prognosis</article-title><source>Dig Dis Sci</source><year>2015</year><volume>60</volume><fpage>1655</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1007/s10620-015-3524-0</pub-id><pub-id pub-id-type="pmid">25686741</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ip</surname><given-names>JY</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name></person-group><article-title>Long non-coding RNAs in nuclear bodies</article-title><source>Develop Growth Differ</source><year>2012</year><volume>54</volume><fpage>44</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/j.1440-169X.2011.01303.x</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutschner</surname><given-names>T</given-names></name><name><surname>Hammerle</surname><given-names>M</given-names></name><name><surname>Diederichs</surname><given-names>S</given-names></name></person-group><article-title>MALAT1 -- a paradigm for long noncoding RNA function in cancer</article-title><source>J Mol Med (Berl)</source><year>2013</year><volume>91</volume><fpage>791</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1007/s00109-013-1028-y</pub-id><pub-id pub-id-type="pmid">23529762</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>CL</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Yu</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Petrovics</surname><given-names>G</given-names></name><name><surname>Kung</surname><given-names>HJ</given-names></name></person-group><article-title>A long noncoding RNA connects c-Myc to tumor metabolism</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>18697</fpage><lpage>18702</lpage><pub-id pub-id-type="doi">10.1073/pnas.1415669112</pub-id><pub-id pub-id-type="pmid">25512540</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Niel</surname><given-names>G</given-names></name><name><surname>D'Angelo</surname><given-names>G</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name></person-group><article-title>Shedding light on the cell biology of extracellular vesicles</article-title><source>Nat Rev Mol Cell Biol</source><year>2018</year><volume>19</volume><fpage>213</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.125</pub-id><pub-id pub-id-type="pmid">29339798</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousefi</surname><given-names>H</given-names></name><name><surname>Maheronnaghsh</surname><given-names>M</given-names></name><name><surname>Molaei</surname><given-names>F</given-names></name><name><surname>Mashouri</surname><given-names>L</given-names></name><name><surname>Reza Aref</surname><given-names>A</given-names></name><name><surname>Momeny</surname><given-names>M</given-names></name><name><surname>Alahari</surname><given-names>SK</given-names></name></person-group><article-title>Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance</article-title><source>Oncogene</source><year>2020</year><volume>39</volume><fpage>953</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-1040-y</pub-id><pub-id pub-id-type="pmid">31601996</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>T</given-names></name><name><surname>Tschannen</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Jacob</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>M</given-names></name><name><surname>Dittmar</surname><given-names>RL</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>M</given-names></name><name><surname>Kohli</surname><given-names>M</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Boardman</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Characterization of human plasma-derived exosomal RNAs by deep sequencing</article-title><source>BMC Genomics</source><year>2013</year><volume>14</volume><fpage>319</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-14-319</pub-id><pub-id pub-id-type="pmid">23663360</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>PP</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>E</given-names></name></person-group><article-title>Extracellular vesicle-packaged HIF-1alpha-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells</article-title><source>Nat Cell Biol</source><year>2019</year><volume>21</volume><fpage>498</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0299-0</pub-id><pub-id pub-id-type="pmid">30936474</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naderi-Meshkin</surname><given-names>H</given-names></name><name><surname>Lai</surname><given-names>X</given-names></name><name><surname>Amirkhah</surname><given-names>R</given-names></name><name><surname>Vera</surname><given-names>J</given-names></name><name><surname>Rasko</surname><given-names>JEJ</given-names></name><name><surname>Schmitz</surname><given-names>U</given-names></name></person-group><article-title>Exosomal lncRNAs and cancer: connecting the missing links</article-title><source>Bioinformatics</source><year>2019</year><volume>35</volume><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty527</pub-id><pub-id pub-id-type="pmid">30649349</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henze</surname><given-names>AT</given-names></name><name><surname>Mazzone</surname><given-names>M</given-names></name></person-group><article-title>The impact of hypoxia on tumor-associated macrophages</article-title><source>J Clin Invest</source><year>2016</year><volume>126</volume><fpage>3672</fpage><lpage>3679</lpage><pub-id pub-id-type="doi">10.1172/JCI84427</pub-id><pub-id pub-id-type="pmid">27482883</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derderian</surname><given-names>C</given-names></name><name><surname>Orunmuyi</surname><given-names>AT</given-names></name><name><surname>Olapade-Olaopa</surname><given-names>EO</given-names></name><name><surname>Ogunwobi</surname><given-names>OO</given-names></name></person-group><article-title>PVT1 signaling is a mediator of Cancer progression</article-title><source>Frontiers Oncol</source><year>2019</year><volume>9</volume><fpage>502</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00502</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><article-title>LncRNA PVT1 regulate expression of HIF1&#x003b1; via functioning as ceRNA for miR-199a-5p in non-small cell lung cancer under hypoxia</article-title><source>Mol Med Rep</source><year>2017</year><volume>17</volume><fpage>1105</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">29115513</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-0978-2</pub-id><pub-id pub-id-type="pmid">30925926</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrondo</surname><given-names>C</given-names></name><name><surname>Flax</surname><given-names>J</given-names></name><name><surname>Kucherov</surname><given-names>V</given-names></name><name><surname>Siebert</surname><given-names>A</given-names></name><name><surname>Osinski</surname><given-names>T</given-names></name><name><surname>Rosenberg</surname><given-names>A</given-names></name><name><surname>Fucile</surname><given-names>C</given-names></name><name><surname>Richheimer</surname><given-names>S</given-names></name><name><surname>Beckham</surname><given-names>CJ</given-names></name></person-group><article-title>Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder Cancer and is contained in bladder Cancer patient urinary exosomes</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0147236</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0147236</pub-id><pub-id pub-id-type="pmid">26800519</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>YM</given-names></name><name><surname>Dong</surname><given-names>LX</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>LY</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>ZZ</given-names></name></person-group><article-title>Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells</article-title><source>J Exp Clin Canc Res</source><year>2019</year><volume>38</volume><fpage>389</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1384-8</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucharzewska</surname><given-names>P</given-names></name><name><surname>Christianson</surname><given-names>HC</given-names></name><name><surname>Welch</surname><given-names>JE</given-names></name><name><surname>Svensson</surname><given-names>KJ</given-names></name><name><surname>Fredlund</surname><given-names>E</given-names></name><name><surname>Ringner</surname><given-names>M</given-names></name><name><surname>Morgelin</surname><given-names>M</given-names></name><name><surname>Bourseau-Guilmain</surname><given-names>E</given-names></name><name><surname>Bengzon</surname><given-names>J</given-names></name><name><surname>Belting</surname><given-names>M</given-names></name></person-group><article-title>Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>7312</fpage><lpage>7317</lpage><pub-id pub-id-type="doi">10.1073/pnas.1220998110</pub-id><pub-id pub-id-type="pmid">23589885</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name></person-group><article-title>Determination of serum Exosomal H19 as a noninvasive biomarker for bladder Cancer diagnosis and prognosis</article-title><source>Med Sci Monitor</source><year>2018</year><volume>24</volume><fpage>9307</fpage><lpage>9316</lpage><pub-id pub-id-type="doi">10.12659/MSM.912018</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>JT</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Partin</surname><given-names>AW</given-names></name><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>I</given-names></name><name><surname>Sokoll</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>DW</given-names></name><name><surname>Lotan</surname><given-names>Y</given-names></name><name><surname>Kibel</surname><given-names>AS</given-names></name><name><surname>Busby</surname><given-names>JE</given-names></name><name><surname>Bidair</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>DW</given-names></name><name><surname>Taneja</surname><given-names>SS</given-names></name><name><surname>Viterbo</surname><given-names>R</given-names></name><name><surname>Joon</surname><given-names>AY</given-names></name><name><surname>Dahlgren</surname><given-names>J</given-names></name><name><surname>Kagan</surname><given-names>J</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Sanda</surname><given-names>MG</given-names></name></person-group><article-title>Can urinary PCA3 supplement PSA in the early detection of prostate Cancer?</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><fpage>4066</fpage><lpage>4072</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.52.8505</pub-id><pub-id pub-id-type="pmid">25385735</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>GZ</given-names></name><name><surname>Jin</surname><given-names>MZ</given-names></name><name><surname>Dai</surname><given-names>JX</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>JH</given-names></name><name><surname>Jin</surname><given-names>WL</given-names></name></person-group><article-title>Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies</article-title><source>Trends Pharmacol Sci</source><year>2017</year><volume>38</volume><fpage>669</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.05.002</pub-id><pub-id pub-id-type="pmid">28602395</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group><article-title>A potential solution for eliminating hypoxia as a cause for radioresistance</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>10548</fpage><lpage>10550</lpage><pub-id pub-id-type="doi">10.1073/pnas.1814212115</pub-id><pub-id pub-id-type="pmid">30301796</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>VS</given-names></name><name><surname>Wiggins</surname><given-names>JM</given-names></name><name><surname>Siemann</surname><given-names>DW</given-names></name></person-group><article-title>Tumor oxygenation and cancer therapy-then and now</article-title><source>Br J Radiol</source><year>2019</year><volume>92</volume><fpage>20170955</fpage><pub-id pub-id-type="pmid">29513032</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milosevic</surname><given-names>M</given-names></name><name><surname>Warde</surname><given-names>P</given-names></name><name><surname>Menard</surname><given-names>C</given-names></name><name><surname>Chung</surname><given-names>P</given-names></name><name><surname>Toi</surname><given-names>A</given-names></name><name><surname>Ishkanian</surname><given-names>A</given-names></name><name><surname>McLean</surname><given-names>M</given-names></name><name><surname>Pintilie</surname><given-names>M</given-names></name><name><surname>Sykes</surname><given-names>J</given-names></name><name><surname>Gospodarowicz</surname><given-names>M</given-names></name><name><surname>Catton</surname><given-names>C</given-names></name><name><surname>Hill</surname><given-names>RP</given-names></name><name><surname>Bristow</surname><given-names>R</given-names></name></person-group><article-title>Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>2108</fpage><lpage>2114</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2711</pub-id><pub-id pub-id-type="pmid">22465832</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strese</surname><given-names>S</given-names></name><name><surname>Fryknas</surname><given-names>M</given-names></name><name><surname>Larsson</surname><given-names>R</given-names></name><name><surname>Gullbo</surname><given-names>J</given-names></name></person-group><article-title>Effects of hypoxia on human cancer cell line chemosensitivity</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>331</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-13-331</pub-id><pub-id pub-id-type="pmid">23829203</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teicher</surname><given-names>BA</given-names></name><name><surname>Lazo</surname><given-names>JS</given-names></name><name><surname>Sartorelli</surname><given-names>AC</given-names></name></person-group><article-title>Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells</article-title><source>Cancer Res</source><year>1981</year><volume>41</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">7448778</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatfield</surname><given-names>SM</given-names></name><name><surname>Sitkovsky</surname><given-names>M</given-names></name></person-group><article-title>A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1alpha driven immunosuppression and improve immunotherapies of cancer</article-title><source>Curr Opin Pharmacol</source><year>2016</year><volume>29</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2016.06.009</pub-id><pub-id pub-id-type="pmid">27429212</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatfield</surname><given-names>SM</given-names></name><name><surname>Kjaergaard</surname><given-names>J</given-names></name><name><surname>Lukashev</surname><given-names>D</given-names></name><name><surname>Schreiber</surname><given-names>TH</given-names></name><name><surname>Belikoff</surname><given-names>B</given-names></name><name><surname>Abbott</surname><given-names>R</given-names></name><name><surname>Sethumadhavan</surname><given-names>S</given-names></name><name><surname>Philbrook</surname><given-names>P</given-names></name><name><surname>Ko</surname><given-names>K</given-names></name><name><surname>Cannici</surname><given-names>R</given-names></name><name><surname>Thayer</surname><given-names>M</given-names></name><name><surname>Rodig</surname><given-names>S</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Jackson</surname><given-names>EK</given-names></name><name><surname>Karger</surname><given-names>B</given-names></name><name><surname>Podack</surname><given-names>ER</given-names></name><name><surname>Ohta</surname><given-names>A</given-names></name><name><surname>Sitkovsky</surname><given-names>MV</given-names></name></person-group><article-title>Immunological mechanisms of the antitumor effects of supplemental oxygenation</article-title><source>Sci Transl Med</source><year>2015</year><volume>7</volume><fpage>277ra30</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa1260</pub-id><pub-id pub-id-type="pmid">4641038</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Facciabene</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Hagemann</surname><given-names>IS</given-names></name><name><surname>Balint</surname><given-names>K</given-names></name><name><surname>Barchetti</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>LP</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Lal</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name></person-group><article-title>Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells</article-title><source>Nature</source><year>2011</year><volume>475</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/nature10169</pub-id><pub-id pub-id-type="pmid">21753853</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noman</surname><given-names>MZ</given-names></name><name><surname>Desantis</surname><given-names>G</given-names></name><name><surname>Janji</surname><given-names>B</given-names></name><name><surname>Hasmim</surname><given-names>M</given-names></name><name><surname>Karray</surname><given-names>S</given-names></name><name><surname>Dessen</surname><given-names>P</given-names></name><name><surname>Bronte</surname><given-names>V</given-names></name><name><surname>Chouaib</surname><given-names>S</given-names></name></person-group><article-title>PD-L1 is a novel direct target of HIF-1&#x003b1;, and its blockade under hypoxia enhanced MDSC-mediated T cell activation</article-title><source>J Exp Medicine</source><year>2014</year><volume>211</volume><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1084/jem.20131916</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>RM</given-names></name><name><surname>Robinson</surname><given-names>SP</given-names></name><name><surname>McPhail</surname><given-names>LD</given-names></name><name><surname>Carter</surname><given-names>ND</given-names></name><name><surname>Murray</surname><given-names>JF</given-names></name></person-group><article-title>Immunohistochemical assessment of intrinsic and extrinsic markers of hypoxia in reproductive tissue: differential expression of HIF1alpha and HIF2alpha in rat oviduct and endometrium</article-title><source>J Mol Histol</source><year>2011</year><volume>42</volume><fpage>341</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1007/s10735-011-9338-2</pub-id><pub-id pub-id-type="pmid">21732047</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BW</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Chung</surname><given-names>JY</given-names></name><name><surname>Conway</surname><given-names>C</given-names></name><name><surname>Ylaya</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Hewitt</surname><given-names>SM</given-names></name></person-group><article-title>Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry</article-title><source>J Transl Med</source><year>2013</year><volume>11</volume><fpage>185</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-11-185</pub-id><pub-id pub-id-type="pmid">23927384</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darfeuille</surname><given-names>F</given-names></name><name><surname>Reigadas</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>JB</given-names></name><name><surname>Orum</surname><given-names>H</given-names></name><name><surname>Di Primo</surname><given-names>C</given-names></name><name><surname>Toulme</surname><given-names>JJ</given-names></name></person-group><article-title>Aptamers targeted to an RNA hairpin show improved specificity compared to that of complementary oligonucleotides</article-title><source>Biochemistry-us</source><year>2006</year><volume>45</volume><fpage>12076</fpage><lpage>12082</lpage><pub-id pub-id-type="doi">10.1021/bi0606344</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;ze&#x0015f;</surname><given-names>AR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zong</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Pilrose</surname><given-names>J</given-names></name><name><surname>Nephew</surname><given-names>KP</given-names></name></person-group><article-title>Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer</article-title><source>Sci Rep-uk</source><year>2017</year><volume>7</volume><fpage>894</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-00966-3</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfranca</surname><given-names>A</given-names></name></person-group><article-title>VEGF therapy: a timely retreat</article-title><source>Cardiovasc Res</source><year>2009</year><volume>83</volume><fpage>611</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp228</pub-id><pub-id pub-id-type="pmid">19578068</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benej</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Vibhute</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Graves</surname><given-names>E</given-names></name><name><surname>Le</surname><given-names>QT</given-names></name><name><surname>Koong</surname><given-names>AC</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Papandreou</surname><given-names>I</given-names></name><name><surname>Denko</surname><given-names>NC</given-names></name></person-group><article-title>Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>10756</fpage><lpage>10761</lpage><pub-id pub-id-type="doi">10.1073/pnas.1808945115</pub-id><pub-id pub-id-type="pmid">30201710</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>F</given-names></name><name><surname>Mendell</surname><given-names>JT</given-names></name></person-group><article-title>Functional classification and experimental dissection of long noncoding RNAs</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>393</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.011</pub-id><pub-id pub-id-type="pmid">29373828</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name></person-group><article-title>Genome-wide methods for investigating long noncoding RNAs</article-title><source>Biomed Pharmacother</source><year>2019</year><volume>111</volume><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.078</pub-id><pub-id pub-id-type="pmid">30594777</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz-Barahona</surname><given-names>A</given-names></name><name><surname>Villar</surname><given-names>D</given-names></name><name><surname>Pescador</surname><given-names>N</given-names></name><name><surname>Amigo</surname><given-names>J</given-names></name><name><surname>del Peso</surname><given-names>L</given-names></name></person-group><article-title>Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><fpage>2332</fpage><lpage>2345</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp1205</pub-id><pub-id pub-id-type="pmid">20061373</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grampp</surname><given-names>S</given-names></name><name><surname>Platt</surname><given-names>JL</given-names></name><name><surname>Lauer</surname><given-names>V</given-names></name><name><surname>Salama</surname><given-names>R</given-names></name><name><surname>Kranz</surname><given-names>F</given-names></name><name><surname>Neumann</surname><given-names>VK</given-names></name><name><surname>Wach</surname><given-names>S</given-names></name><name><surname>Stohr</surname><given-names>C</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Eckardt</surname><given-names>KU</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name><name><surname>Schodel</surname><given-names>J</given-names></name></person-group><article-title>Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>13183</fpage><pub-id pub-id-type="doi">10.1038/ncomms13183</pub-id><pub-id pub-id-type="pmid">27774982</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grampp</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>V</given-names></name><name><surname>Salama</surname><given-names>R</given-names></name><name><surname>Lauer</surname><given-names>V</given-names></name><name><surname>Kranz</surname><given-names>F</given-names></name><name><surname>Platt</surname><given-names>JL</given-names></name><name><surname>Smythies</surname><given-names>J</given-names></name><name><surname>Choudhry</surname><given-names>H</given-names></name><name><surname>Goppelt-Struebe</surname><given-names>M</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name><name><surname>Schodel</surname><given-names>J</given-names></name></person-group><article-title>Multiple renal cancer susceptibility polymorphisms modulate the HIF pathway</article-title><source>PLoS Genet</source><year>2017</year><volume>13</volume><fpage>e1006872</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1006872</pub-id><pub-id pub-id-type="pmid">28715484</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Roosbroeck</surname><given-names>K</given-names></name><name><surname>Pollet</surname><given-names>J</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>miRNAs and long noncoding RNAs as biomarkers in human diseases</article-title><source>Expert Rev Mol Diagn</source><year>2013</year><volume>13</volume><fpage>183</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1586/erm.12.134</pub-id><pub-id pub-id-type="pmid">23477558</pub-id></element-citation></ref></ref-list></back></article>